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Hepatocellular carcinoma (HCC), generally known as primary liver cancer, is the fifth 
most common malignancy in the world. It is also the third leading cause of cancer-
related deaths worldwide, with a mortality rate comparable to its incidence rate. This 
high mortality rate can be significantly lowered if diagnosis is made early and 
curative treatments are provided in time. Since 80% of HCCs arise from a cirrhotic 
background, the detection of cirrhosis can aid risk stratification for early HCC 
detection. Early biomarkers of cirrhosis and HCC are therefore urgently needed.  
 
In this work, we aim to identify cirrhosis- and HCC-associated autoantibodies that can 
serve as biomarkers in the early detection of HCC. Autoantibodies against tumour-
associated antigens have been detected in cancer patients’ sera. These autoantibodies 
are elicited during early carcinogenesis, and are possibly the earliest cancer 
biomarkers that can be detected in sera. Hence, they facilitate the development of 
non-invasive serological tests for early cancer detection.  
 
In this study, tumour proteins were separated by 2-DE before being transferred onto 
PVDF membranes and probed with patient or control sera. The immunoreactive 
profiles were compared and twelve cirrhosis- and HCC-associated antigenic spots 
were detected and identified by tandem mass spectrometry. In addition, their identities 
were independently verified by commercial antibodies. These autoantigens were also 
analyzed to determine if they were differentially regulated or post-translationally 
modified by either phosphorylation or glycosylation. Six of these autoantigens can 
potentially form a biomarker panel for the detection of cirrhosis and HCC. In 
conclusion, this study identified a distinct repertoire of cirrhosis- and HCC-associated 
autoantibodies that can potentially enable early HCC diagnosis.  
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1.1. HEPATOCELLULAR CARCINOMA 
 
1.1.1. Hepatocellular Carcinoma 
 
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the 
fifth most common malignancy in the world (Kuntz and Kuntz, 2006; Parkin et al., 
2001). It is also the third leading cause of cancer-related death worldwide, with a 
mortality rate comparable to its incidence rate. The survival rate after the onset of 
symptoms is generally less than one year (Hoofnagle, 2004; Marrero, 2006).  
 
Historically, HCC has been more prevalent in developing countries such as Asia. 
While this heterogeneous geographical distribution is still maintained, formerly low-
incidence countries, particularly Europe and the USA, have been witnessing a rising 
HCC incidence for the past decade (Seeff and Hoofnagle, 2006). HCC incidence and 
mortality rates in these countries are anticipated to double over the next two decades. 
As a result, much interest has been generated in the study of this malignancy (Llovet 
et al., 2003; Thorgeirsson et al., 2006). 
 
There are two chief factors contributing to the high mortality of HCC. One is the late 
presentation of HCC, where the dearth of symptoms at the early stage of the disease 
results in detection of cancer only when at an advanced stage (Usatoff and Habib, 
2002). Another is the paucity of curative treatments for late-stage HCC. Consequently, 
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in most cases, by the time diagnosis is made, no curative treatment is available 
(Hoofnagle, 2004).  
 
1.1.2. HCC Carcinogenesis 
 
HCC carcinogenesis is initiated and propagated by a plethora of genetic, epigenetic, 
and environmental factors. This multi-step carcinogenesis process commonly begins 
with chronic liver injury, followed by fibrogenesis and cirrhogenesis (Section 1.1.6.1). 
These processes are complemented by chronic inflammation, which is accompanied 
by the production of reactive oxygen species that in turn causes DNA damage. DNA 
damage characterized by gene amplification, deletion or mutation hastens the rate of 
carcinogenesis and contributes to the formation of dysplastic hepatocytes, and 
eventually, dysplastic nodules, resulting in the emergence of HCC.  
 
Despite efforts to elucidate the molecular pathology leading to HCC development, no 
genetic predisposition for HCC has been found. In fact, the molecular profile of HCC 
tumours has been markedly dissimilar, even in tumours arising from the same patient. 
However, while the specific genes perturbed in different HCC cases do not overlap, 
the molecular pathways disrupted generally do. Hence, the (1) cell cycle control 
pathway, (2) cell-cell interaction and signal transduction pathway, (3) DNA damage 
response pathway, (4) growth inhibition and apoptotic pathways, (5) angiogenesis 
pathway and (6) DNA methylation pathway are often disrupted in HCC (Bruix et al., 
2004; Cha and DeMatteo, 2005; Chen et al., 2002a; Elchuri et al., 2005; Rocken and 
Carl-McGrath, 2001; Tannapfel and Wittekind, 2002; Thomas and Zhu, 2005; 





The tumour, nodes, metastasis (TNM) staging system (Table 1.1; Table 1.2) is 
frequently used to determine the degree of tumour progression in HCC. Staging is 
based on the size, number and distribution of the primary lesion and also on the 
presence of vascular invasion, lymph node involvement and distant metastases (Kudo, 




HCC, like most cancers, is a multifactorial disease. Common risk factors for HCC 
include male sex, old age, chronic Hepatitis B virus (HBV) or Hepatitis C virus (HCV) 
infection, cirrhosis, exposure to aflatoxin B1, alcohol abuse, and metabolic disorders 
like haemochromatosis and tyrosinema. Recently, Marrero et al. (2005a) reported that 
alcohol, tobacco and obesity are independent synergistic risk factors for HCC, but the 
validity of this finding is still under debate (Huo et al., 2005). Chronic HBV infection 
and cirrhosis are considered major risk factors for HCC (Anthony, 2002; Colombo 








Table 1.1. The TNM staging of HCC. 
 
T Primary tumour 
TX Primary tumour cannot be accessed 
T0 No evidence of primary tumour 
T1 Solitary tumour 2 cm or less in greatest dimension without vascular invasion 
T2 Solitary tumour 2 cm or less in greatest dimension with vascular invasion; 
 
Or multiple tumours, limited to one lobe, none more than 2 cm in greatest 
dimension without vascular invasion; 
 
Or solitary tumour more than 2 cm in greatest dimension without vascular 
invasion 
T3 Solitary tumour more than 2 cm in greatest dimension with vascular invasion; 
 
Or multiple tumours limited to one lobe, none more than 2 cm in greatest 
dimension with vascular invasion;  
 
Or multiple tumours limited to one lobe, any one tumour more than 2 cm in 
greatest dimension with or without vascular invasion 
T4 Multiple tumours in more than one lobe; 
 
Or any invasion of major branch of portal or hepatic vein 
N Regional lymph nodes 
NX Regional lymph nodes cannot be accessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M Distant metastasis 
MX Distant metastasis cannot be accessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Table 1.2. Stage grouping of HCC. 
 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage IIIA T3 N0 M0 
Stage IIIB T1 / T2 / T3 N1 M0 
Stage IVA T4 Any N M0 
Stage IVB Any T Any N M1 
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1.1.5. Chronic HBV Infection  
 
Persistent infection with HBV is one of the most important risk factors for HCC. A 
1988 study estimated that chronic HBV infection accounted for 75 – 90% of HCC 
cases worldwide (Safary and Beck, 2000), while a recent report attributed 53% of 
global HCC cases to HBV infection (Perz et al., 2006). This decrease is probably due 
to the implementation of childhood HBV vaccination programs in several countries. 
 
1.1.5.1. Evidence of an Association between Chronic HBV Infection and HCC 
 
Several lines of evidence have converged to support the association between chronic 
HBV infection and HCC incidence. Epidemiological studies showed that the global 
geographical distributions of HBsAg-positive (Hepatitis B virus surface antigen-
positive) HBV carriers and HCC patients coincide with a correlation coefficient of 
0.67, p<0.001 (Bosch and Ribes, 2002). Case-control studies found that the 
prevalence of HBV infection markers – HBsAg and anti-HBc (Hepatitis B core 
protein) – is significantly higher among HCC patients than among healthy individuals 
or patients with other cancers (Johnson, 1994). Prospective studies confirmed that 
HBV infection precedes HCC onset and determined that chronic HBV carriers who 
were infected during childhood are a hundred times more likely than non-carriers to 
develop HCC (Johnson, 1994; Llovet et al., 2003). Animal viruses that are closely 
related to HBV have also been shown to promote HCC development in animal models: 
for instance, the woodchuck hepatitis virus (WHV) induces liver cancer in almost all 
chronically infected animals (Johnson, 1994; Rabe et al., 2001). Moreover, countries 
that implemented a HBV vaccination program reported reduced HCC incidence 
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(Safary and Beck, 2000). In Taiwan, for example, where HBV infection is endemic, 
HCC incidence decreased four-fold together with the decrease of HBV carriers 
following implementation of a universal infant immunization program against HBV. 
When analyzed relative to birth cohorts, HCC incidence dropped from 0.52 to 0.13 
per 100,000 children (Chang et al., 1997; Teo and Fock, 2001). These statistics imply 
that a decrease in chronic HBV infection in the population would lead to a decrease in 
HCC development, further supporting the association between chronic HBV infection 
and HCC incidence.  
 
1.1.5.2. HBV-induced Carcinogenesis 
 
The progression of HBV-induced HCC is illustrated in Figure 1.1. HBV infection is 
postulated to promote liver cancer development via several mechanisms: (1) indirectly 
by inducing liver inflammation, (2) directly by integrating into the host genome, (3) 
through action of the HBV X protein (HBx), and (4) through interaction with other 
etiological factors (Cougot et al., 2005; Johnson, 2002; Kremsdorf et al., 2006).  
 
By itself, HBV is thought to be non-cytopathic because liver cancer develops a long 
time after HBV infection and even then, most HCC cases are initiated against a 
cirrhosis background (Cougot et al., 2005). Moreover, although many patients suffer 
liver damage upon HBV infection, some do not, even as viral replication persists 
(Johnson, 2002). As such, HBV is proposed to induce HCC pathogenesis via an 















Well Differentiated  
HCC 
Figure 1.1. Development of HBV-associated HCC. Chronic HBV infection 
results in prolonged liver inflammation and liver injury, thereby inducing iterative 
rounds of liver regeneration. In the face of chronic liver injury and sustained liver 
regeneration, liver fibrosis develops, progressing to cirrhosis and ultimately, HCC. 
Alternatively, in a minority of cases, chronic HBV infection can promote HCC 
development without causing cirrhosis. (Pictures from http://health-pictures.com) 
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In this scenario, HBV infection activates cytotoxic T lymphocytes that proceed to 
destroy infected hepatocytes in order to eradicate the virus (Johnson, 2002). Chronic 
HBV infection causes chronic liver inflammation and continual liver cell death, which 
in turn triggers iterative rounds of liver regeneration. Thereafter, cirrhosis may ensue, 
followed by HCC development. The repeated rounds of liver injury and regeneration 
may also promote oxidative DNA damage and genomic instability, thereby increasing 
the risk of cancer (Cougot et al., 2005; Johnson, 2002).  
 
Conversely, evidence is accumulating for the direct role of HBV in causing HCC. 
HBV is a hepadnavirus with a circular double-stranded DNA genome. Being a DNA 
virus, HBV has a potential for integrating into the host genome. This integration event 
is not essential for viral replication, but allows the persistence of viral DNA in the 
host cell. Integrated HBV DNA is reportedly detected in 70% of HCC cases. Related 
studies have revealed that HBV integrates into host genome prior to liver cancer 
development (Kremsdorf et al., 2006), thus supporting the involvement of viral DNA 
integration in carcinogenesis. In WHV-related HCC, it is clear that carcinogenesis is 
promoted with the cis-activation of N-myc2 following the integration of WHV DNA 
into the proto-oncogene. In contrast, HBV does not consistently integrate into specific 
proto-oncogenes, although it has been found to integrate into the telomerase gene as 
well as genes involved in cell signaling, proliferation and viability (Brechot, 2004; 
Kremsdorf et al., 2006). The significance of this finding with pertinence to HCC 
development remains controversial (Cougot et al., 2005; Johnson, 2002). Instead of 
cis-activation of proto-oncogenes, HBV DNA integration is believed to induce 
carcinogenesis by promoting genomic instability in the presence of chronic liver 
inflammation and regeneration. The latter induces deletions and rearrangements of the 
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integrated viral sequences. These sequences are also known to transpose from one 
chromosome to another, taking with them flanking cellular sequences. The resulting 
genomic instability promotes cancer development.   
 
A colossal amount of studies has been conducted in examining the importance of HBx 
in HBV-induced carcinogenesis.  This interest is generated largely due to the highly 
conserved nature of HBx, its ability to trigger host immune responses, its persistence 
throughout chronic hepatitis, its transactivation activities, its interaction with cellular 
proteins, and its role in controlling cell proliferation and viability. Despite the intense 
study, a specific mechanism whereby HBx promotes carcinogenesis has not been 
discovered. One reason is that HBx transactivates a plethora of cellular proteins and 
promoters via protein-protein interactions. To demonstrate, HBx was reported to 
inhibit apoptosis and promote cell proliferation by interacting with p53 (Elmore et 
al.,1997) ; blocking caspase 3 activity (Gottlob et al., 1998); affecting mitochondria 
function (Shirakata and Koike, 2003) ; upregulating survivin (Zhang et al., 2005b); 
upregulating the transcriptional activity of proto-oncogenes (c-Myc, c-jun) and 
transcription factors (NFκB, activating protein-1) (Lucito and Schneider, 1992; 
Tanaka et al., 2006; Twu et al., 1993) ; and upregulating amongst other signaling 
pathways, the Ras-Raf-MAPK signal transduction pathway, the JAK/STAT pathway 
and the protein kinase B pathway (Chirillo et al., 1996; Lee and Yun, 1998; Zhang et 
al., 2006). Under certain circumstances, HBx is also known to exert pro-apoptotic 
functions by regulating the expressions of Fas/FasL, Bax/Bcl-2 and other proteins 
(Kim and Seong, 2003; Miao et al., 2006; Pollicino et al., 1998). In addition, HBx is 
suggested to promote carcinogenesis by modulating proteasome function, 
upregulating pro-angiogenesis factors and inducing cellular migration through 
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activation of matrix metalloproteinase 3 and 9 (Chung et al., 2004b; Lee et al., 2000; 
Yu et al., 2005) . HBx is also thought to induce HCC in conjunction with aflatoxins 
and other carcinogens (Brechot, 2004; Johnson, 2002; Kremsdorf et al., 2006; Zhang 
et al., 2006). Hence, it is evident that HBx plays a vital role in HBV-induced 
carcinogenesis. 
 
Other HBV proteins, including the truncated pre-S2/S envelope protein and the novel 
HBV spliced protein, have similarly been hypothesized to affect carcinogenesis 
(Brechot, 2004). Based on all these findings, a clear conclusion is that HBV infection 
promotes carcinogenesis through a myriad of synergistic mechanisms. Moreover, the 
importance of each mechanism in inducing HCC development likely differs from 
patient to patient.   
 
1.1.6. Liver Cirrhosis 
 
Like HCC, cirrhosis is a complex multi-etiological disease; the inevitable corollary of 
various chronic liver diseases. Notably, the consequences of cirrhosis are independent 
of the primary etiology. Cirrhosis is characterized by the replacement of normal liver 
tissue with fibrous tissue and the conversion of normal liver architecture into 
structurally abnormal nodules; hepatocytes and other liver cells are damaged and 
blood circulation in the liver is disrupted (Crawford, 2002; Kuntz and Kuntz, 2006).   
 
Independent of other risk factors, cirrhosis is the single most significant risk factor for 
the development of HCC (Colombo and Sangiovanni, 2003). Indeed, it is described as 
a pre-neoplastic stage that often precedes HCC. Reportedly, 80% to 90% of HCC 
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cases develop against a cirrhotic background (Brown and Scharschmidt, 1999), and 
cirrhotic patients have an annual HCC incidence of 2.0 to 6.6% as opposed to non-
cirrhotic patients, whose HCC incidence is 0.4% (Llovet et al., 2003). 
 
Any form of cirrhosis can lead to HCC, but HBV and HCV infection, alcoholic liver 
disease and hereditary haemochromatosis are the most frequent antecedents 
(Crawford, 2002; Kuntz and Kuntz, 2006). In particular, a study by Perz et al. (2006) 
attributed 30% of cirrhosis cases to HBV. Cirrhosis and HBV infection are likely to 
be synergistic risk factors for HCC. In fact, chronic HBV-infected patients with 
cirrhosis are more prone to HCC than their counterparts without cirrhosis. In countries 
of high HBV endemicity, patients with HBV infection and cirrhosis have a 3-fold 
higher risk of developing HCC than those with HBV infection but not cirrhosis and a 
16-fold higher HCC risk than inactive carriers (Fattovich et al., 2004). 
 
 The severity of cirrhosis is also linked to the risk of HCC. Cirrhosis is staged 
clinically with the Child’s-Pugh classification (Table 1.3), which utilizes 5 parameters 
– ascites, serum albumin, serum bilirubin, encephalopathy and nutritional status – to 
distinguish the degree of liver impairment. Child’s-Pugh A denotes cirrhosis with 
minimal liver damage; Child’s-Pugh C, advanced cirrhosis whereby some liver 
proteins are not produced and complications such as jaundice, ascites (fluid 
accumulation in the abdomen) and encephalopathy exist; and Child’s-Pugh B, an 
intermediate condition. Generally, patients with Child’s-Pugh C have a higher risk of 
developing HCC than those with Child’s-Pugh A or B (Brown and Scharschmidt, 
1999). This implies that excessive liver damage promotes HCC development.  
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The gold standard for confirmation of cirrhosis is liver biopsy which is obviously not 
a popular diagnostic test (Crawford, 2002). Recently, Kim et al. (2004) have 
identified a unique gene signature in the tissue samples of patients with cirrhosis that 
could serve as biomarkers. The gene signature consisted of genes that were 
differentially regulated in cirrhotic patients. The utility of this gene signature as a 
cirrhotic biomarker remains to be validated, especially as diagnostic tests 
incorporating this gene signature would require liver biopsy. The search for cirrhotic 
biomarkers which can be tested by non-invasive serological means is thus ongoing. 
 
Table 1.3. Child’s-Pugh grading of severity of liver disease.  
 
 Patient score for increasing abnormality 
 1 2 3 
 
   
Ascites None Mild Moderate 
Encephalopathy None 1 or 2 3 or 4 
Serum bilirubin 
µmol/l 16 – 33 33 – 50 > 50 
Serum albumin g/dl > 3.5 2.8 – 3.5 < 2.7 
Prothrombin time (s) 1 – 4 4.1 – 6 > 6 
 
   
Grade A  
(Child’s-Pugh A) Score 5 – 6 cirrhosis with minimal liver damage 
Grade B  
(Child’s-Pugh B) Score 7 – 9 
an intermediate condition of Child’s-Pugh 
A and C 
Grade C  
(Child’s-Pugh C) Score 10 – 15 
advanced cirrhosis whereby some liver 
proteins are not produced and 
complications such as jaundice, ascites 
(fluid accumulation in the abdomen) and 
encephalopathy exist 
 





1.1.6.1. Cirrhogenesis and Carcinogenesis 
 
Any agent that inflicts chronic liver injury can ultimately lead to cirrhosis. The three 
key pathological mechanisms involved are cell death, fibrosis and regeneration. 
Injured liver cells stimulate the release of chemotactic cytokines, growth factors and 
proteases, and inflammatory cell recruitment and infiltration.  In response to liver cell 
death and inflammation, reparative liver regeneration is initiated. This involves the 
enhancement of cellular division and the differentiation and multiplication of liver 
stem cells. The regeneration process is generally able to restore normal liver histo-
architecture and liver functions. However, chronic liver injury results in incomplete 
regeneration and fibrosis occurs, characterized by the laying of excess extracellular 
matrix in the liver. The extracellular matrix is deposited by activated myofibroblast-
like hepatic stellate cells. Over a period of time, self-perpetuating rounds of chronic 
liver injury, fibrosis and regeneration results in the formation of scar tissue and the 
lobular architecture of the liver is disrupted. Cirrhosis is thus established. 
 
The molecular mechanism behind the progression of cirrhosis to HCC remains to be 
elucidated. However, it is highly likely that the persistent inflammation and excessive 
cellular proliferation inherent in cirrhosis predispose the liver to DNA damage, 
mitotic errors and ultimately, genomic instability, which in turn potentiates 
carcinogenesis (Crawford, 2002; Guicciardi and Gores, 2005; Iredale, 2003; Kuntz 
and Kuntz, 2006). Some of the genes found to be disrupted in cirrhosis include those 
involved in matrix remodeling, cell-cell interaction, immunologic and anti-apoptotic 
pathways (Kim et al., 2004; Llovet and Wurmbach, 2004). 
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1.1.7. Diagnosis of HCC 
 
The gold standard for HCC diagnosis is the histological examination of the hepatic 
mass (Marrero, 2006). Due to the potential complications of biopsy, including risk of 
haemorrhage and tumour seeding, non-invasive imaging techniques have been used to 
examine the liver for lesions. The commonly used imaging techniques are ultrasound, 
computer tomography and magnetic resonance imaging (Kuntz and Kuntz, 2006).  
 
In terms of serum biomarkers, alpha fetoprotein (AFP) is still the best available for 
HCC diagnosis (Brown and Scharschmidt, 1999). It is a normal serum protein 
synthesized primarily during embryonic development but is maintained at a low 
concentration of less than 20 ng/ml in healthy, non-pregnant adults. Elevated serum 
AFP levels are observed in pregnant ladies and patients with chronic liver disease. 
Consequently, AFP is sufficiently specific for HCC only when its serum levels rise 
above 500 ng/ml. This implies that AFP cannot detect small HCC tumours and also 
indicates that AFP is a fairly specific but insensitive marker for HCC (Lopez, 2005). 
To counteract this, des-γ-carboxy prothrombin (DCP), a serum protein that has 50 – 
60% positivity in HCC, is sometimes used in combination with AFP for HCC 
diagnosis; a method which some clinicians deem superior to the use of a single 
biomarker test (Kuntz and Kuntz, 2006; Lopez, 2005). A glycoform (AFP-L3) and an 
isoform (Band +II) of AFP demonstrating higher specificities have also been 




The diagnostic criteria for HCC based on ultrasound or biopsy are described in Table 
1.4 (Bruix et al., 2006). Alternatively, HCC is diagnosed if a lesion that is more than 
2 cm in diameter is observed with two imaging tests showing hypervascularity or if an 
AFP concentration greater than 400 ng/ml is detected with one imaging test showing 
hypervascularity (Marrero, 2006).  
 
 
Table 1.4. Diagnostic criteria for Hepatocellular carcinoma. (Adapted from Bruix 
et al, 2006) 
 
 Cyto-histological data (biopsy required) 
 Non-invasive criteria (cirrhotic patients; biopsy not required) 
1. Focal lesion ≤ 2cm. Two imaging techniques with arterial 
hypervascularization and venous washout 
 
2. Focal lesion > 2cm. One imaging technique with arterial 
hypervascularization and venous washout 
 
Techniques to be considered: contrast ultrasound, dynamic computed tomography and 




1.1.8. Management of HBV-associated HCC 
 
1.1.8.1. Prevention  
 
The best ‘treatment’ for HBV-associated HCC is prevention. If chronic HBV 
infection is not established, HBV-associated HCC would be a non-issue (Lok, 2004). 
Fortunately, a vaccine for HBV is available, and the implementation of universal 
HBV vaccination programs has reduced HBsAg carrier rates and HCC incidence 
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significantly. This is irrefutably demonstrated by epidemiologic data: before HBV 
vaccination, the HBsAg carrier rate in children was 0.3% in Japan, 3.4% in Korea, 5 – 
10% in Singapore, 10 – 20% in Taiwan, and 2.5% in Thailand; after HBV vaccination, 
HBsAg carrier rates dropped to 0.03% in Japan, 0.9% in Korea, <1% in Singapore, 
0.8 – 1.7% in Taiwan, and 0.7% in Thailand (Chang, 2006). Moreover, as mentioned 
previously, HCC incidence declined upon implementation of the HBV vaccination 
program in Taiwan.  
 
1.1.8.2. Antiviral Therapy 
 
Once chronic HBV infection is established, treatment efforts should focus on 
preventing the progression to cirrhosis. There are several antiviral therapy options 
available, utilizing interferon-α and the nucleoside analogs lamivudine and adefovir 
dipivoxil. However, these antiviral therapies are not suitable for every patient. 
Moreover, while antiviral treatment may slow or even halt the progression towards 
cirrhosis, it cannot eradicate HBV and so the risk of HCC is not completely 
eliminated. Long-term antiviral treatment is likely required to repress viral replication 
and unfortunately, drug resistance has arisen with the use of some established 
antiviral drugs, especially lamivudine. New antiviral agents are being developed but 
their efficacy has not been clarified (Feng and Lok, 2005; Osborn and Lok, 2006; 
Wong and Lok; 2006). Interestingly, the use of small interfering RNAs (siRNAs) as 
therapeutic options has been investigated and siRNAs have been shown to reduce 
HBV replication and serum HBV levels in mice (Morrissey et al., 2005a; Morrissey et 
al. 2005b; Romano et al., 2006). This work marks progress towards RNAi-based 
therapeutics although more studies have to be conducted before siRNAs become 
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clinically viable treatment options, especially since siRNAs have been found to 
produce potentially adverse immunostimulatory effects in mammals (Marques and 
Williams, 2005).  
 
1.1.8.3. Reversal of Cirrhosis 
 
To date, no curative treatments have been presented for cirrhosis (Bruix et al., 2004). 
Antiviral drugs such as lamivudine have been proposed to decrease HCC incidence in 
patients with HBV-associated cirrhosis, but such treatments merely slow the 
progression of cirrhosis and do not cure it (Hoofnagle, 2004; Kuntz and Kuntz, 2006). 
Indeed, it is widely thought that cirrhosis is irreversible (Kuntz and Kuntz, 2006). 
Scattered reports of cirrhosis reversal have surfaced, but most demonstrate reversal of 
fibrosis in cirrhosis rather than reversal of cirrhosis per se (Desmet, 2005). However, 
there exist a few cases of bona fide cirrhosis reversal, giving rise to the hypothesis 
that early-stage cirrhosis can be cured, especially in younger patients (Desmet, 2005; 
Iredale, 2003). In fact, the spontaneous reversion of HBV-associated cirrhosis has 
been reported (Bortolotti et al., 2005).  
 
1.1.8.4. Treatment of HCC 
 
Several options for the treatment of HCC are available, although only surgical 
resection of the tumour, liver transplantation, and percutaneous ablation are curative 
(Llovet et al., 2003; Marrero, 2006). Palliative treatment options include arterial 
embolization, chemotherapy and thermotherapy (Bruix et al., 2004; Llovet et al., 
2003; Usatoff and Habib, 2002). In terms of treatment strategy, the Barcelona Clinic 
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Liver Cancer (BCLC) staging system (Figure 1.2) is deemed superior in guiding 
treatment (Kudo, 2006; Marrero, 2006). However, views on the prognostic efficacy of 
the BCLC system is largely divided (Kudo, 2006; Marrero et al., 2005b; Pascual et al., 
2006). 
 
Resection is generally the treatment of choice for non-cirrhotic patients and patients 
with solitary tumours and well-preserved liver function. Survival of such patients can 
reach 60 – 70% at 5 years, but the tumour recurrence rate is high (70% at 5 years) 
(Forner et al., 2006; Llovet et al., 2003). Liver transplantation can potentially offer 
long term survivals (70% at 5 years) with low recurrence rates (15%), but only when 
the tumour is not in an advanced stage (Fuster et al., 2005). Percutaneous ablations, 
using either radiofrequency or ethanol, are the best treatment options for early 
unresectable HCC (Llovet et al., 2003; Marrero, 2006). Notably, clinical studies 
































Figure 1.2. BCLC staging and treatment strategy for HCC patients. 
The Okuda staging system is based on the presence or absence of ascites, tumour 
volume >50% of liver, serum albumin < 30 g/L, and serum bilirubin > 30 mg/L 
(Usatoff and Habib, 2002). PST = performance status test. N = nodules. M = 
metastases. PEI = percutaneous ethanol injection. * Cadaveric liver transplantation or 
living donor liver transplantation. (Reproduced from Llovet et al, 2003; reprinted with 
permission of Elsevier Limited) 
 
1.1.8.5. Surveillance of Individuals at Risk 
 
Aside from prevention, early detection via surveillance is likely the only other 
strategy that can ameliorate HCC-related mortality rates (Bruix et al., 2004). HCC 
satisfies several criteria for a surveillance program. First, it is a prevalent disease 
worldwide with high mortality rates. Second, its risk factors are well-defined such that 
a target population at risk of developing HCC – patients with cirrhosis – is easily 
identified. Third, curative treatments such as resection or liver transplantation are 
available at the early stages of cancer. Fourth, non-invasive low-cost screening tests 
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based on ultrasound and serum AFP tests are available (Bolondi, 2003; Shetty et al., 
2002).  
 
Several countries, including Singapore, have adopted screening for HCC in cirrhotic 
patients; implementing a surveillance program consisting of 6-monthly ultrasound and 
serum AFP tests1. The recommended diagnostic algorithm upon detection of a hepatic 



























Figure 1.3. Diagnostic algorithm for hepatic nodule detected in a cirrhotic liver 
by ultrasound. Surveillance for HCC in cirrhotic patients is based on serum AFP 
levels and ultrasound tests that are conducted every half a year. The above diagnostic 
strategy is provided as a reference in the event that a hepatic nodule is detected. US = 
ultrasound. (Reproduced from Bruix and Sherman, 2005; reprinted with permission of 
Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, Inc.). 
 
                                                
1
 The twice-yearly surveillance schedule is employed based on the average tumour doubling time of 
HCC, which is 180 days (Shetty et al., 2004). 
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Surprisingly, it is unproven that surveillance actually lowers mortality rates 
significantly (Llovet et al., 2003; Shetty et al., 2004). Due to ethical reasons, only one 
randomized controlled trial has been conducted to evaluate the efficacy of 
surveillance in reducing HCC-related mortality (Shetty et al., 2002; Zhang et al., 
2004). Promising results were obtained where screening of HCC based on twice-
yearly ultrasound and serum AFP tests reduced HCC mortality by 37%. Whether this 
survival benefit can be demonstrated worldwide remains to be seen as all the test 
subjects were from China and adherence rates in the screened group were low 
(58.2%). Moreover, disease-specific mortality was measured instead of all-cause 
mortality so the impact of the surveillance program may not be completely 
represented. Various cohort and meta-studies have concluded that screening for HCC 
can identify tumours at an early stage, resulting in more patients having a higher 
chance of receiving curative treatment, thereby prolonging survival rates (McMahon 
et al., 2000; Oka et al., 1990; Shetty et al., 2002; Trevisani et al., 2004; Yuen et al., 
2000; Zoli et al., 1996). However, these studies are mostly retrospective and do not 
account adequately for lead time bias or overdiagnosis (De Masi et al., 2005). On 
another note, the definition of the target population for screening is also under debate. 
For surveillance to be cost-effective, only those who can be treated if diagnosed with 
HCC should be screened. As such, there is a prevailing view that patients with late-
stage cirrhosis (Child’s-Pugh C) should not be screened. It is also thought that patients 
with chronic HBV infection without cirrhosis need not be screened since there is a 





1.1.9. Need for Biomarkers that allow Early Cancer Detection 
 
Current screening and diagnostic tests for HCC involve a combination of ultrasound 
and serum AFP testing. AFP has a low sensitivity (40 – 65%), a variable specificity 
(75 – 90%) and a low positive predictive value (12%) (Farinati et al., 2006; Fung and 
Lok, 2005). Ultrasound fares better with a sensitivity of 100%, a specificity of 98% 
and a positive predictive value of 78% (Tong et al., 2001). However, the efficacy of 
ultrasound is operator-dependent and against a cirrhotic background, small tumours 
cannot be detected easily (Brown and Scharschmidt, 1999; Llovet et al, 2003).  
 
Despite the low sensitivity of AFP as a HCC biomarker, it is still utilized as a HCC 
screening and diagnostic test for several reasons: (i) its long history, (ii) its relatively 
low cost, (iii) its accessibility, and (iv) the lack of biomarkers that can justify its 
replacement (Brown and Scharschmidt, 1999; Lopez, 2005). In light of this, there is 
an impetus to find new biomarkers that are more sensitive and specific for HCC and 
that can detect HCC early. 
 
1.1.9.1. The Search for New HCC Biomarkers 
 
In light of the limitations of AFP as a HCC biomarker, researchers have been actively 
searching for alternative biomarkers. A plethora of potential biomarkers has been 
found, but their efficacy remains to be investigated through clinical trials (Pang et al., 
2008; Wright et al., 2007; Zhou et al., 2006). 
 
  23
In terms of serum biomarkers, as discussed, a glycoform (AFP-L3) and an isoform 
(Band + II) of AFP have been proposed to be more specific than AFP in diagnosing 
HCC. AFP-L3 can be detected in approximately 35% of HCC patients with small 
tumours (< 3 cm) (Ho et al, 1996; Johnson et al, 1997; Li et al, 2001; Zhou et al,, 
2006). Another serum biomarker, known as DCP, has been found to be more specific 
than AFP, but is less sensitive. DCP serum levels are elevated in 50 – 60% of HCC 
patients but in 15 – 30% of patients with small tumours (Nomura et al., 1996; Pang et 
al., 2008; Weitz and Liebman, 1993). Some studies have shown that testing for both 
AFP and DCP increases the specificity and sensitivity for diagnosing HCC (Pang et 
al., 2008). Glypican-3 (GPC-3) is another serum biomarker that has been widely 
studied. It can be detected in 40 – 53 % of HCC patients and is not detectable in 
healthy individuals (Capurro et al., 2003; Nakatsura et al., 2003; Pang et al., 2008). 
Combination testing of both GPC-3 and AFP can increase sensitivity for diagnosing 
HCC (Pang et al., 2008).   
 
Aside from the four more established new HCC serum biomarkers discussed above, 
many other serum biomarkers have been found. Some examples are gamma-glutamyl 
transferase, alpha-l-fucosidase, transforming growth factor-beta-1, insulin-like growth 
factor-II and golgi protein 73 (Pang et al., 2008; Wright et al., 2007; Zhou et al., 
2006).  
 
Tumour-associated autoantigens (TAAs) and their corresponding tumour-associated 
autoantibodies can also serve as biomarkers for diagnosing HCC. Two of the more 
established HCC-associated TAAs are p53 (Raedle et al, 1998; Soussi, 2000) and p62 
(Lu et al, 2001; Zhang and Chan, 2002). Many other TAAs have been discovered. For 
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instance, Stenner-Liewen et al (2000) found 19 distinct antigens associated to HCC, 
of which 3 are novel. Wang et al (2002) identified 55 cDNA sequences that could 
code for HCC-associated antigens. Uemura et al (2003) uncovered 27 TAAs. Le 
Naour et al (2002) identified 8 TAAs, but only 1 (autoantibody against a novel 
truncated form of calreticulin) is commonly induced in HCC. Zhou et al (2005) 
identified HCC-22-5 as a TAA. Takashima et al (2006) identified 4 TAAs. Li et al 
(2008) identified 6 TAAs. These TAAs remain to be validated.  
 
 
1.1.10. The Ideal Biomarker 
 
Biomarkers are indispensable tools for detecting, staging, monitoring and controlling 
cancer (Wulfkuhle et al., 2003; Srinivas et al., 2001). They are cellular, biochemical, 
and molecular (proteomic, genetic, and epigenetic) alterations that indicate the 
physiological state of a cell, be it normal or pathological. With respect to cancer, 
biomarkers refer to substances (Wagner et al., 2004) or proteomic patterns (Petricoin 
et al., 2002; Haleem et al., 2003) that highlight the presence of cancer in the body. 
They can be compounds secreted by the tumour itself or a result of a specific response 
of the body to the presence of cancer. Generally, biomarkers are measurable in tissues, 
cells or fluids, but to minimize trauma and cost of screening while maximizing utility, 
biomarkers should ideally be measurable in serum, urine or saliva (Wagner et al., 
2004).  
 
The ideal cancer biomarker should be highly sensitive and specific for a particular 
cancer type (Wagner et al., 2004). For instance, patients with HCC should test 
positive for the biomarker, and people without should test negative. Unfortunately, 
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few such biomarkers exist (Poon and Johnson, 2001). A panel of biomarkers would 
offer better sensitivity and specificity compared to a single biomarker, but there is still 
a need for biomarkers that are highly sensitive, specific and easily accessible in 
biological fluids (Omenn, 2006; Zolg, 2006). 
 
1.2. TUMOUR IMMUNOLOGY 
 
1.2.1. The Humoral Response to Cancer 
 
In the course of carcinogenesis, autoantibodies against some self-proteins are 
produced. Most of these autologous proteins, commonly referred to as tumour-
associated antigens (TAA), are altered in a way that renders them immunogenic 
(Anderson and LaBaer, 2005; Casiano et al., 2006; Miles et al., 2006; Sahin et al., 
1995; Utz and Anderson, 1998). These proteins could be over-expressed, mutated, 
mis-folded, or aberrantly degraded. They could also have been subjected to post-
translational modifications; glycosylated proteins in particular are thought to be 
highly immunogenic. Cancer-testis antigens that are normally only found in germ-line 
cells (e.g. testis and embryonic ovaries) and oncofetal proteins that are aberrantly 
expressed in tumours are also known TAAs. In addition, proteins that are aberrantly 
localized can provoke a humoral response. This is illustrated prominently in the case 
of p53, whose immunogenicity is believed to be initiated in part by its accumulation 
in the cancer cell cytosol and nucleus (Salazar and Disis, 2003; Stockert et al., 1998; 
Soussi, 2000; Tan, 2001).  
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It is not entirely clear how these modifications lead to the generation of 
autoantibodies, especially since many TAAs are intracellular proteins. One popular 
hypothesis involves aberrant tumour cell death, when the modified intracellular 
proteins are released and presented to the immune system in an inflammatory 
environment (Madrid, 2005). Aberrant tumour cell death can refer to defective 
apoptosis, ineffective clearance of apoptotic cells or other forms of cell death such as 
necrosis (Utz and Anderson, 1998). Repeated cycles of such aberrant tumour cell 
death can lead to persistent exposure of modified intracellular proteins, priming the 
immune system to perceive such tumour-associated proteins as foreign. Another 
interesting hypothesis was proposed by Oppenheim et al. (2005) who discovered that 
some TAAs, when released upon apoptosis, can initiate migration of leukocytes and 
immature dendritic cells by interacting with specific G-protein-coupled receptors on 
these cells. It is proposed that this chemotactic activity of tissue-specific TAAs served 
to alert the immune system to danger signals from damaged tissues, promoting tissue 
repair. TAAs that interact with immature dendritic cells are immunogenic because 
they are liable to be sequestered and, subsequently, presented to the cellular immune 
system.  
 
Other postulations attempting to explain the generation of autoantibodies exist 
(Anderson and LaBaer, 2005; Casiano et al., 2006; Houghton et al., 2001; Salazar and 
Disis, 2003). TAAs that have undergone post-translational modifications may be 
perceived as foreign by the immune system. TAAs that bear structural similarity to 
cross-reacting foreign antigens may also elicit a humoral response (mimicry). TAAs 
that bind to heat shock proteins tend to be immunogenic due to the 
immunomodulatory properties of the heat shock proteins (Coronella-Wood and Hersh, 
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2003; Li, 2003). Intracellular proteins that are re-localized to the tumour cell surface 
may appear unfamiliar, thereby triggering an immune response. Cancer-testis antigens 
or over-expressed proteins may conceivably overcome the immune tolerance towards 
self-proteins (Sahin et al., 1995; Tan, 2001). Tumour-associated peptides that are 
found in blood are potentially antigenic. These peptides could originate from tumour 
intracellular proteins or endogenous circulating proteins (Chignard et al., 2006; Liotta 
and Petricoin, 2006; Villanueva et al., 2006). In the case of the former, Chignard et al. 
(2006) found calreticulin fragments in the sera of HCC patients. In the case of the 
latter, Villanueva et al. (2006) discovered that tumours secrete exoproteases that 
cleave products of the ex vivo coagulation and complement degradation pathways, 
generating tumour-specific peptides. The immunogenicity of such peptides remains to 
be studied.  
 
1.2.2. Autoantibodies and Carcinogenesis 
 
There is no conclusive evidence that autoantibodies play a direct role in cancer 
pathogenesis. Rather, they have been regarded as reporters identifying aberrant 
cellular mechanisms and molecular pathways involved in carcinogenesis. This is 
especially since many TAAs are oncoproteins (e.g. Her-2/Neu, c-myc and ras) or 
cellular proteins that are involved in carcinogenesis (e.g. p53 and cyclin B1). 
Furthermore, it is believed that autoantibodies can be cancer-type specific and can 
highlight the molecular pathways perturbed in a particular cancer (Casiano et al., 
2006; Salazar and Disis, 2003; Soussi, 2000; Tan, 2001). 
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Autoantibodies have also been associated with cancer progression. Imai et al. (1993) 
reported a higher frequency of autoantibody-positive HCC patients (33%) compared 
to patients with cirrhosis (14%) or chronic hepatitis (13%). The same trend was 
observed in another study (Covini et al., 1997). Moreover, Zhang et al. (2001) 
detected de novo autoantibody responses against proteins involved in cell survival and 
proliferation (p62 and CENP-F) during the transition from cirrhosis to HCC. The 
presence of autoantibodies has also been known to indicate a poor prognosis or 
potential recurrence of cancer. In addition, autoantibodies have been shown to 
disappear after tumour resection; anti-p53 autoantibodies disappeared after resection 
in 27 patients with colorectal cancer. However, autoantibodies do not always correlate 
positively with tumour burden. In one study, 20% of early-stage breast cancer patients 
were autoantibody-positive compared to 7% of late-stage breast and ovarian cancer 
patients, suggesting that autoantibodies may be protective (Anderson and Labaer, 
2005; Pfreundschuh et al., 2003). Yet, there is evidence that tumours can lose 
expression of tumour antigens via immune selection (Rosenberg, 2001), and this can 
similarly explain the decrease in autoantibody titer in late-stage cancer.  
 
Admon and Shoshan (2006) proposed that autoantibodies targeting cell surface 
hormone receptors on the tumour cells could cause oligomerization of the receptors, 
thereby activating them such that growth signals are transmitted to the tumour cells. 
Uncontrolled cellular proliferation may ensue, leading to tumour growth. This 





1.2.3. Anti-Tumour Effects of Autoantibodies 
 
Theoretically, autoantibodies against tumour membrane proteins could inflict 
immunological assaults on the tumour cells through complement activation, antibody-
dependent cytotoxicity or interference with receptor/ligand interactions (Anderson 
and LaBaer, 2005; Lollini et al., 2006). The efficacy of trastuzumab, a monoclonal 
antibody against Her-2/Neu, in breast cancer therapy further suggests that 
autoantibodies may have potent anti-tumour effects (Coronella-Wood and Hersh, 
2003; Lollini et al., 2006). Yet, tumour regression is not known to be effected by the 
physiological anti-tumour response. This is attributed in large to the failure of 
autoantibodies in reaching high titers because of tolerance mechanisms (Coronella-
Wood and Hersh, 2003; Houghton et al., 2001; Janeway et al., 2005).  
 
While the humoral immune response is important in tumour immunotherapy, the T-
cell mediated immune response is thought to be crucial in tumour suppression (Ilan et 
al., 1997; Rosenberg, 2001). Since the development of a humoral response is 
associated with the MHC class I-mediated cytotoxic T cell response, autoantibodies 
can lead to the identification of T cell antigens (Pfreundschuh et al., 2003; Radvanyi, 
2004; Sahin et al., 1995). This is instrumental in the development of therapeutic 
cancer vaccines that can target TAAs such that cancer cells, but not normal cells, are 
attacked by the cellular immune response. Indeed, DNA cancer vaccines against Her-
2/Neu have reduced tumour development significantly in mice and NY-ESO-1, a 
cancer-testis antigen found in melanoma and other cancers, has been used as an 
immunogen in several clinical trials (Anderson and LaBaer, 2005; Haupt et al., 2002). 
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1.2.4. Autoantibodies as Biomarkers for Early Cancer Detection 
 
Ultimately, the key contribution of tumour immunology lies in early cancer detection. 
The immune response occurs at an early stage during tumourigenesis and 
autoantibodies can be detected before any other biomarkers or phenotypic aberrations 
are observed, rendering such autoantibodies indispensable as biomarkers for early 
cancer detection (Madrid, 2005; Shin et al., 2003). 
 
There are numerous advantages in utilizing autoantibodies as biomarkers (Anderson 
and LaBaer, 2005; Casiano et al., 2006; Comtesse et al., 2000; Li et al., 2006; Salazar 
and Disis, 2003). Firstly, autoantibodies against most TAAs are seldom detected in 
normal individuals. Secondly, autoantibodies against TAAs are found in the sera of 
cancer patients where they remain accessible to screening. Thirdly, autoantibodies are 
stable and persist in the serum for a relatively long time since they are generally not 
subjected to the types of proteolysis observed for other polypeptides. The persistence 
and stability of the autoantibodies give them an advantage over other biomarkers, 
including the TAAs, which may be rapidly degraded or cleared. In addition, the 
autoantibodies are present in considerably higher concentrations than their respective 
TAAs; many autoantibodies are produced in response to a single autoantigen. 
Consequently, autoantibodies may be more readily detectable compared to their 
corresponding autoantigens. Lastly, sample collection is simplified due to the long 
half-life (7 days) of the autoantibodies, which minimizes hourly fluctuations. Assay 




For all its advantages, a single autoantibody test lacks the sensitivity and specificity 
required for cancer screening and diagnosis. Typically, autoantibodies against a 
particular TAA are found in only 10 – 30% of patients (Casiano et al., 2006). The 
reason for this low sensitivity lies in the heterogeneity of cancer, whereby different 
proteins are aberrantly processed or regulated in patients with the same cancer type. 
Hence no protein is likely to be similarly perturbed or immunogenic across a 
particular cancer. On the other hand, some TAAs, for instance p53, are observed in 
different cancer types and so lack discrimination power in diagnosing a specific 
cancer. Certain TAAs may also be non-specific as they arise in both cancer and other 
diseases, particularly those with an autoimmune background.   
 
Although a single autoantibody would lack adequate sensitivity and specificity, a 
panel of TAAs enabling the analysis of multiple autoantibodies improves matters 
considerably, presumably because there is a higher possibility that a patient will 
respond to at least one of the antigens (Anderson and LaBaer, 2005; Casiano et al., 
2006; Zhang, 2004). Indeed, using a panel of seven TAAs, Koziol et al. (2003) were 
able to identify normal individuals and discriminate between patients with breast, 
colon, gastric, HCC, lung or prostate cancer with sensitivities ranging from 77 – 92% 
and specificities ranging from 85 – 91%. Moreover, after adding one TAA to the 
original seven, Zhang et al. (2007) demonstrated a significantly higher frequency of 
autoantibody-positive HCC patients (58.9%) compared to patients with chronic 
hepatitis (20%), cirrhosis (30%) and normal individuals (12.2%). In contrast, antibody 
frequency to any one TAA in the panel is low, varying from 9.9 – 21.8% in HCC 
patients. These results hint of the high sensitivity and specificity that a carefully 
selected TAA panel can achieve in cancer diagnosis. 
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1.2.5. Methods in Identifying Autoantibodies 
 
There are numerous methods that can be employed to identify TAAs and their 
corresponding autoantibodies (Gunawardana and Diamandis, 2007; Huang et al., 
2004; Imai et al., 1993). In recent years, four of these methods encompassing 
serological screening of complementary DNA (cDNA) expression libraries, phage 
display libraries, protein microarrays, and 2-D Western blots, respectively, have 
dominated the tumour immunology field. In contrast to the conventional one-TAA-at-
a-time approach, a common characteristic of these methods is that many TAAs can be 
discovered simultaneously. 
 
1.2.5.1. Serological Identification of Antigens by Recombinant Expression 
Cloning (SEREX) 
 
SEREX involves the identification of TAAs by screening patient sera against a cDNA 
expression library obtained from the autologous tumour (Sahin et al., 1995; Preuss et 
al., 2002). A formidable number of TAAs associated with numerous cancer types 
have been identified by this method and these are documented in a public access 
online database (Chen et al., 2005; Pfreundschuh et al., 2003; Scanlan et al., 2001; 
Stenner-Liewen et al., 2000; Tureci et al., 2005).  
 
There are, however, some limitations to the SEREX approach (Madrid et al., 2005; 
Miles et al., 2006). Firstly, TAAs identified by SEREX are mainly linear epitopes and 
tend to be gene products that can be expressed in bacteria. Secondly, there is a bias 
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towards antigens that are highly expressed in the tumour. Thirdly, SEREX is labour-
intensive and not amenable to automation. Lastly, post-translational modifications 
cannot be detected, and these modifications are thought to be highly antigenic. 
Possible improvements to the SEREX approach have been suggested. One proposal 
involves the screening of cDNA libraries with allogenic sera together with autologous 
sera to eliminate non-cancer-specific and patient-specific antigens. Another involves 
the construction of cDNA libraries from cancer cell lines. The use of eukaryotic 
expression systems have also been proposed (Casiano et al., 2006; Madrid et al., 2005; 
Preuss et al., 2002; Pfreundschuh et al., 2003; Seliger and Kellner, 2002; Zhang, 
2004). 
 
1.2.5.2. Phage Display 
 
A recent approach based on phage display was reported by Mintz et al. (2003).  In this 
method, a cDNA phage display library is constructed using a particular tumour or 
cancer cell line. Peptides from the tumour or cell line are expressed as fusions with 
phage proteins and are displayed on the phage surface. Autoantibodies in patient 
serum are captured by the phage display library through successive rounds of 
immunoprecipitation and the corresponding antigens are sequenced and identified 
(Anderson and LaBaer, 2005; Casiano et al., 2006; Hanash, 2003; Mintz et al., 2003). 
TAAs for prostate and ovarian cancers, amongst others, have been identified with this 
approach (Fossa et al., 2004; Vidal et al., 2004). Some caveats associated with this 
technique include the need to sequence each immunoreactive phage clone and the 
preclusion of conformational epitopes. In addition, as with SEREX, post-translational 
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modifications cannot be detected with this method (Anderson and LaBaer, 2005; 
Fossa et al., 2004; Wang et al., 2005).   
 
Recently, some groups have identified TAAs by serological screening of phage 
protein microarrays, combining phage display and protein microarray technology. 
Immunoreactive phage clones were selected via biopanning, arrayed onto glass slides 
(Wang et al., 2005) or nitrocellulose membranes (Chatterjee et al., 2006), and 
subjected to more serological screenings. TAA panels yielding reasonable sensitivities 
and specificities for ovarian (Chatterjee et al., 2006) and prostate cancer (Wang et al., 
2005) have been identified in this way.  
 
1.2.5.3. Protein Microarrays 
 
There are essentially two types of protein micoarrays: forward-phase or reverse-phase 
microarrays (Balboni et al., 2006). Antibodies against known proteins are spotted on 
the forward-phase protein microarray whereas either purified or recombinant proteins 
or fractionated cancer cell lysates are arrayed on reverse-phase protein microarrays. 
For the purpose of identifying TAAs and their corresponding autoantibodies, reverse-
phase protein microarrays are utilized.  
 
Protein microarrays enable high throughput and scalable analysis. However, studies 
using reverse-phase protein microarrays are hampered by the short shelf-life of 
arrayed proteins and difficulties in purifying or producing protein targets (Anderson 
and LaBaer, 2005; Ramachandran et al., 2004). To circumvent this, natural protein 
microarrays are invented whereby cancer cell lysates instead of pure proteins are 
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spotted (Madoz-Gurpide et al., 2001; Qiu et al., 2004). Madoz-Gurpide et al. (2001) 
combined liquid-phase separations with microarray technology to detect 
autoantibodies to tumour antigens. Cell lysates are fractionated by liquid-based 
separation methods and the fractions are arrayed onto appropriate surfaces, generating 
natural protein microarrays. With such microarrays, Madoz-Gurpide et al. (2001) 
bypassed the problem of producing purified proteins but encountered another: reactive 
proteins could not be easily identified; only reactive fractions could. They attempted 
to elucidate patterns of reactivity instead, but this is highly reminiscent of a similar 
technique, SELDI (surface enhanced laser desorption and ionization), which yields 
protein peak patterns instead of protein identities (Check, 2004; Diamandis, 2003; 
Petricoin and Liotta, 2003).  
 
In an alternate bid to combat the protein problem, Ramachandran et al. (2004) devised 
self-assembling protein microarrays that effectively obviated the need for purified 
proteins and side-stepped protein storage problems. Target cDNAs are printed onto 
glass slides and transcribed and translated in situ in a cell-free expression system. The 
resulting proteins can then be screened accordingly. The self-assembling protein 
microarray yields an advantage over the natural protein microarray in that it allows 
TAAs to be identified readily. 
 
Recently, Qin et al. (2006) presented a reverse-capture microarray based on the dual-
antibody sandwich ELISA. Cancer cell lysates are incubated with commercial 
antibody arrays so that antigens are immobilized in their native configuration. 
Meanwhile, Immunoglobulin Gs (IgG) from patient and control sera are purified and 
labeled respectively with different fluorescent dyes. The differentially-labeled IgGs 
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are then incubated with the antigen-bound microarrays. Consequently, autoantibodies 
that are cancer-specific can be identified. The reverse-capture microarray removes the 
need for recombinant proteins, and allows the instant identification of cancer-specific 
autoantibodies. More significantly, it enables the analysis of native antigens. However, 
only known antigens with commercially available antibodies can be analyzed. 
Furthermore, immunoreactivity with post-translationally modified antigens cannot be 
differentiated unless antibodies that can specifically and exclusively bind to such 
antigens are commercially available.  
 
1.2.5.4. SERPA (Serological Proteome Analysis) 
 
A proteomics-based approach, termed SERPA, that is rapidly gaining favour involves 
the discovery of TAAs using a combination of two-dimensional electrophoresis (2-
DE), Western blot, and mass spectrometry (Chung et al., 2004a; Klade et al., 2001; 
Nakanishi et al., 2006; Takashima et al., 2006; Zou et al., 2005). Proteins from 
tumour tissues or cell lines are separated by 2-DE, transferred onto membranes by 
electro-blotting and subsequently probed with sera from healthy or cancer volunteers. 
The respective immunoreactive profiles are compared and the cancer-associated 
antigenic spots are identified by mass spectrometry. Due to the nature of Western 
blots, only denatured epitopes can be detected (Casiano et al., 2006; Seliger and 
Kellner, 2002). TAAs for various cancers have been identified with this approach, 
including distinct truncated versions of calreticulin in HCC and pancreatic cancer, 
DEAD-box protein 48 in pancreatic cancer, RS/DJ-1 in breast cancer, protein gene 
product 9.5, annexins I and II in lung cancer, and Rho GDP dissociation inhibitor 2 in 
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acute leukemia (Brichory et al., 2001a;b; Cui et al., 2005; Hong et al., 2004; Le 
Naour et al., 2001; Le Naour et al., 2002; Xia et al., 2005). 
 
2-DE is indisputably the classical technique for proteome analysis. Proteins are 
separated in the first dimension according to their isoelectric points (pI) and in the 
second dimension according to their molecular weight (Hunter et al., 2002). Despite 
some limitations (Rabilloud, 2002), 2-DE is still the best method for the high 
resolution separation of a large number of proteins, and its efficacy in distinguishing 
post-translationally modified proteins and protein isoforms is unparalleled. 
Consequently, when coupled to Western blot for serological screening, TAAs that 
have undergone post-translational modifications can be detected. Most of these 
antigens can be subsequently identified with the aid of mass spectrometry.  
 
1.2.6. The Importance of Studying the Proteome 
 
A point to note is that SEREX and phage display relies on the cDNA complement – 
i.e. transcriptome – of cancer cells whereas SERPA and to a certain extent protein 
microarrays analyzes the protein complement – i.e. proteome – of cancer cells directly. 
With SEREX and phage display, cDNAs are translated in the bacterial or phage 
system and the cancer proteome thus achieved may not be representative of a cancer 
cell (as explained below). In contrast, a proteomics-based approach enables proteins 
and peptides in their modified states, as they occur in cancer cells, to be screened for 
immunoreactivity with autoantibodies in patient serum (Shin et al., 2002).   
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The transcriptome of a cell does not reflect its proteome in its entirety; many distinct 
sets of proteomes can be derived from a set of transcriptome (Hanash, 2004). A 
cDNA library obtained from tumour cells is likely to yield a proteome dissimilar to 
that of the cancer cell. Firstly, post-translational modifications are not encoded in the 
transcriptome, and so, are not likely to be preserved. Secondly, protein isoforms can 
arise from a single mRNA transcript due to the use of alternative transcription start 
and stop sites, differential mRNA splicing and co-translational modification. Indeed 
studies have suggested an average of three to more than six protein isoforms per gene 
(Wilkins et al., 1996). Consequently, when only the transcriptome is analyzed, 
information on protein isoforms is lost. In addition, since only a subset of protein 
isoforms may be immunogenic (Casiano et al., 2006), isoforms that are immunogenic 
cannot be segregated from those that are not. Thirdly, the mRNA and expressed 
protein level in a cell have also been demonstrated to correlate poorly (Anderson and 
Seilhamer, 1997; Gygi et al., 1999), with a correlation coefficient of only 0.48 (Gygi 
et al., 1999). Fourthly, protein expression and function are context dependent and are 
affected by other factors – including cellular and environment factors like pH, 
hypoxia and drug administration – besides genetic ones (Selby, 2000). Hence, a 
proteome constructed from a cDNA library is likely to differ from the bona fide 
cancer cell proteome. Consequently, proteomics-based approaches such as SERPA 
would be more suitable for the discovery of disease-associated autoantibodies from 






1.3. AIMS OF PROJECT 
 
HBV-associated HCC is a major cause of morbidity and mortality especially in 
developing countries. In Singapore, HCC is the fourth most common cancer in males; 
chronic HBV infection is also a major cause for concern (Sim and Ooi, 2003). 
Biomarkers that enable the early detection or diagnosis of HBV-associated HCC are 
urgently needed to lower the HCC-induced mortality rates.  
 
Autoantibodies against TAAs can be found in HBV-associated HCC patients and 
those that can be detected in the early stage of the disease can facilitate early 
diagnosis. Autoantibodies that manifest in cirrhosis patients are also of particular 
interest because cirrhosis generally precedes HBV-associated HCC development. 
Cirrhosis-associated autoantibodies can thus highlight individuals at risk of 
developing HCC and aid risk stratification for early HCC detection. 
 
This study aims to identify cirrhosis- and HCC-associated autoantibodies that enable 










2. MATERIALS AND METHODS 
 
2.1. LIVER TISSUES AND HUMAN SERA  
 
The liver tissues and sera used in the preliminary study were obtained from patients 
diagnosed with cirrhosis, moderately differentiated HCC, and poorly differentiated 
HCC respectively. The liver tumour tissue used subsequently in the study as an 
antigenic source was obtained from a patient with moderately differentiated HCC 
(Table 2.1, patient 5). Sera were obtained from fifteen patients with liver disease. All 
of the fifteen patients suffered from cirrhosis and chronic HBV infection. Of this 
group of patients, five had cirrhosis but not HCC; five had moderately differentiated 
HCC; and five had poorly differentiated HCC. The diagnosis of the patients was 
verified by histology. The clinical data of the patients are presented in Table 2.1. Sera 
from four healthy individuals were used as controls.  
 
To evaluate the expression levels of the autoantigens in moderately differentiated and 
poorly differentiated HCC tissue lysates, liver tissues from five patients with 
moderately differentiated HCC and seven patients with poorly differentiated HCC 
were analyzed. Paired tumourous and non-tumourous regions of the liver were 
obtained from each patient. The clinical data of these twelve patients are shown in 
Table 2.2. 
 





Table 2.1. Clinical characteristics of 15 patients with liver disease. 
 
Patient Diagnosis Cirrhosis HBV Gender Race Age 
1 Moderately Differentiated 
HCC 
+ + M Chinese 32 
2 Moderately Differentiated 
HCC 
+ + M Indonesia
n 
65 
3 Moderately Differentiated 
HCC 
+ + F Chinese 82 
4 Moderately Differentiated 
HCC 
+ + M Indonesia
n 
67 
5 Moderately Differentiated 
HCC 
+ + M Chinese 53 
6 Poorly Differentiated 
HCC 
+ + M Chinese 52 
7 Poorly Differentiated 
HCC 
+ + M Indian 66 
8 Poorly Differentiated 
HCC 
+ + M Chinese 48 
9 Poorly Differentiated 
HCC 
+ + M Chinese 63 
10 Poorly Differentiated 
HCC 
+ + M Chinese 61 
11 Cirrhosis + + M Chinese 52 
12 Cirrhosis with dysplastic 
nodule 
+ + M Chinese 57 
13 Micronodular Cirrhosis + + M Chinese 49 
14 Micro and Macronodular 
Cirrhosis 
+ + M Chinese 52 













Table 2.2. Clinical characteristics of 12 patients with liver disease. Paired 
tumourous and non-tumourous regions of liver tissue from these patients were 
analyzed.  
 
Patient Diagnosis Cirrhosis HBV Gender Race Age 
1 Moderately Differentiated 
HCC 
+ + M Chinese 32 
2 Moderately Differentiated 
HCC 
+ + M Chinese 40 
3 Moderately Differentiated 
HCC 
+ + M Chinese 63 
4 Moderately Differentiated 
HCC 
+ + M Chinese 
 
42 
5 Moderately Differentiated 
HCC 
+ + M Chinese 69 
6 Poorly Differentiated 
HCC 
+ + M Indian 66 
7 Poorly Differentiated 
HCC 
+ + M Chinese 53 
8 Poorly Differentiated 
HCC 
+ + M Chinese 63 
9 Poorly Differentiated 
HCC 
+ + M Chinese 66 
10 Poorly Differentiated 
HCC 
+ + M Chinese 61 
11 Cirrhosis + + M Chinese 61 
12 Cirrhosis with dysplastic 
nodule 














2.2. SAMPLE PREPARATION 
 
Human liver tissue was ground into fine powder in liquid nitrogen and solubilized in a 
cocktail of 7M urea (USB, Cleveland, OH, USA), 2M thiourea (Fluka, Buchs, 
Switzerland), 4% (w/v) 3-[(3-cholamidopropyl)dimethylaminonio]-1-
propanesulphonate (CHAPS) (USB), 10mM tris(hydroxymethyl)aminomethane (Tris) 
(USB), 1X protease inhibitor cocktail (Pierce, Rockford, IL), 50ug/ml DNase I (from 
bovine pancreas, grade II ) and 50ug/ml RNase A (from bovine pancreas). This 
solution was centrifuged at 100,000g for 2h at 18oC using the Beckman TL-100 
Tabletop Ultracentrifuge (Palo Alto, CA, USA). Thereafter, the supernatant (tissue 
lysate) was collected and stored at -151oC until use. Protein estimation was carried out 
using the Coomassie® Plus Protein Assay Reagent Kit (Pierce) with minor 
modifications to the original protocol; bovine serum albumin (BSA) (Bio-Rad, 




2.3.1. Two-Dimensional Gel Electrophoresis (2-DE) 
 
2.3.1.1. Isoelectric Focusing on IPG (Immobilized pH gradient) Strips 
 
Eighteen-centimetre non-linear (NL) gradient pH 3 – 10 precast ImmobilineTM 
DryStrip gels (GE Healthcare) were rehydrated passively overnight for at least 10 
hours in an Immobiline™ DryStrip Reswelling Tray (GE Healthcare). Each IPG strip 
was rehydrated with 350 µl of rehydration buffer consisting of 7M urea, 2M thiourea, 
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4% (w/v) CHAPS, 20mM dithiothreitol (DTT) (Bio-Rad), 0.2% (v/v) pH 3 – 10 NL 
IPG buffer (GE Healthcare) and trace amounts of bromophenol blue (GE Healthcare). 
The IPG strips were overlaid with a low viscosity Immobiline DryStrip Cover Fluid 
(GE Healthcare) to minimize evaporation and urea crystallization.  
 
Rehydrated IPG strips were transferred onto the Ettan IPGphor Manifold (GE 
Healthcare), which in turn was placed on a flatbed Ettan IPGphor Electrophoretic 
Unit (GE Healthcare) for isoelectric focusing. Liver tissue lysates, each containing 
200 µg of proteins, 20mM DTT and 0.5% (v/v) pH 3 – 10 NL IPG buffer, were 
loaded onto the anodic end of each IPG strip using a loading cup. 108 ml of the cover 
fluid was then applied evenly in the twelve manifold channels. 
 
Isoelectric focusing was performed as followed at a maximum current setting of 50 
µA per strip at 20oC for a total of 40350 Vhr: (i) 200 V, 600 Vhr; (ii) 500 V, 1000 
Vhr; (iii) 1000 V, 500 Vhr; (iv) 8000 V, 2250 Vhr; and (v) 8000 V, 36000 Vhr. 
Voltage was increased linearly for step (iv) and in a step-wise manner for all the other 
steps. The IPG strips were stored at -80oC before the second dimension separation. 
 
2.3.1.2. IPG Strip Equilibration 
 
Prior to the second dimension sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), the IPG strips were subjected to two equilibration steps. 
Each IPG strip was first equilibrated for 15 min in 10 ml of a buffer containing 6M 
urea, 30% (v/v) glycerol (Merck, Darmstadt, Germany), 50mM Tris-HCl (pH 6.8), 
1% (w/v) DTT, 2% (w/v) SDS (Bio-Rad), and 0.002% (w/v) bromophenol blue dye. 
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After the reduction step, the strips were alkylated for 15 min in a similar buffer with 
DTT replaced by 2.5% (w/v) iodoacetamide (IAA; Fluka); this was buffered at pH 8.8. 
 
2.3.1.3. Second Dimension Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS – PAGE) 
 
After equilibration, the IPG strips were transferred onto 12.5% (v/v) polyacrylamide 
gels (1.0 mm thick) and sealed in place with 0.75% (w/v) agarose. SDS-PAGE was 
performed using PROTEAN-II XL electrophoresis cells (Bio-Rad) at a constant 
current of 15 mA per gel for the first 20 min and 30 mA per gel for the rest of the run. 
Running buffer consisting of 0.025M Tris, 0.192M glycine (USB), and 0.1% (w/v) 
SDS was used.  
 




Before blotting, Immun-BlotTM polyvinylidene fluoride (PVDF) membranes (Bio-Rad) 
were pre-wet with 100% (v/v) methanol and equilibrated for at least 5 min in transfer 
buffer. 2-D gels that had been designated for blotting were similarly equilibrated in 
transfer buffer. 
 
Proteins were transferred electrophoretically onto size-matched PVDF membranes 
with the Trans-Blot electrophoretic transfer cell (Bio-Rad). The transfer buffer was 
made up of 20% (v/v) methanol, 0.025M Tris, 0.192M glycine, and 0.1% (w/v) SDS. 
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After blotting, the membranes were incubated in blocking buffer with constant 
rocking at room temperature for at least 1 h before they were kept overnight at 4oC to 
prevent milk spoilage.  The blocking buffer contained 5% (w/v) dry non-fat milk 
dissolved in TBST: 20mM Tris, 150mM sodium chloride (NaCl) (Lab-Scan, Bangkok, 




Following the blocking step, the membranes were rinsed with TBST and incubated 
for 2 h at room temperature with either patient or control serum. The human sera 
served as a source of primary antibody and were diluted 1:100 times with 1% (w/v) 
dry non-fat milk in TBST. Subsequently, the sera were discarded and the membranes 
were subjected to three 15-min washes with 50 ml of TBST per membrane. The 
membranes were then incubated with horseradish peroxidase-conjugated sheep anti-
human IgG antibodies (GE Healthcare). The secondary antibody concentration was 
diluted 1:5000 times and the incubation lasted for 1 h at room temperature. The 
membranes were then washed thrice as before.  
 
Immunodetection was accomplished with the Enhanced Chemiluminescence (ECLTM) 
Detection System (GE Healthcare) followed by exposure on Biomax film (Eastman 
Kodak). 
2.3.2.3. Colloidal Silver Staining 
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Proteins on the PVDF membranes were visualized after immunodetection by colloidal 
silver staining as described by Vettermann et al. (2002). Briefly, the membranes were 
washed in ultra-pure water and stained under agitation with a colloidal staining 
solution prepared immediately before use. The colloidal staining solution consisted of 
40% (w/v) sodium citrate dehydrate (Merck), 20% (w/v) ferrous sulfate heptahydrate 
(freshly prepared) (Merck), and 20% (w/v) silver nitrate (freshly prepared). Staining 
was stopped by washing the membranes in ultra-pure water. The membranes were 
then air-dried and scanned using the ImageScanner. 
 
2.3.3. Silver Staining 
 
Polyacrylamide gels to be stained were removed from the glass plates for silver 
staining. The gels were fixed in 50% (v/v) methanol (Merck), 12% (v/v) acetic acid 
(Merck) and 0.05% (v/v) formalin (Merck) for at least 2 h. They were then subjected 
to three 20-min washes with 35% (v/v) ethanol (Merck) before being sensitized in 
0.02% (w/v) sodium thiosulphate (Merck) for 2 min. The gels were then washed 
thrice with ultra-pure water for 5 min each. Subsequently, they were incubated in 
0.2% (w/v) silver nitrate (Merck) and 0.076% (v/v) formalin for 20 min. This was 
followed by two 1-min rinses with ultra-pure water. The gels were then developed in 
6% (w/v) sodium carbonate (Kanto Chemical, Tokyo, Japan), 0.004% (v/v) sodium 
thiosulphate (Merck) and 0.05% (v/v) formalin. Upon attaining the desired intensity, 
the developer was replaced by 1.46% (w/v) sodium ethylenediaminetetraacetic acid 
(EDTA) (Scharlau Chemie, Barcelona, Spain) to stop the reaction. After incubation 
for 20 min with the stop solution, the gels were washed thrice with ultra-pure water 
for 5 min each. Every step was conducted with constant shaking on an orbital shaker. 
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Silver stained gels were visualized with ImageScanner using Image Master Lab Scan 
v3.01 software (GE Healthcare). 
 
2.3.4. Tandem Mass Spectrometry 
 
2.3.4.1. Enzymatic Digestion of Protein Spots 
 
Immunoreactive protein spots exhibiting cancer specificity were correlated to and 
located on a parallel silver-stained 2-D gel and marked for excision. The gel was 
rinsed twice in ultra-pure water before the protein spots were manually excised and 
transferred to 96-well polypropylene microtiter plates (Nalge Nunc, Roskilde, 
Denmark). Each excised spot was immersed in 150 µl of 50% (v/v) acetonitrile (ACN; 
Applied Biosystems, Forster City, USA), 2.5mM ammonium bicarbonate (NH4HCO3; 
Sigma) washing buffer for at least 24 h at 4oC. The plates were sealed with adhesive 
film to prevent drying.  
 
After incubation, the washing buffer was aspirated and 150 µl of fresh washing buffer 
was added. The plates were sealed again and were incubated at 37oC for 10 min with 
constant shaking. The washing buffer was then removed and the gel spots were dried 
in a Savant Automatic Environmental Speed Vac AE2010 centrifugal concentrator 
(Holbrook, NY, USA). Following that, 20 µl of 10mM DTT in 100mM NH4HCO3 
was added to each gel spot. The plates were sealed and incubated at 56oC for 1 h, after 
which the DTT solution was removed and 20 µl of 55mM IAA in 100mM NH4HCO3 
was added to each gel spot
.
 Incubation was carried out in the dark at room 
temperature for 45 min. Subsequently, IAA was replaced with 100 µl of 100mM 
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NH4HCO3 and the plates were incubated for 10 min at 37oC. NH4HCO3 was then 
replaced with 100 µl of ACN and the plates were incubated for 10 min at room 
temperature.  
 
The two incubation steps with NH4HCO3 and ACN were repeated once in the same 
order and after that, 0.2 µg of sequence grade modified trypsin (Promega, Madison, 
USA) dissolved in 25mM NH4HCO3 was added to each gel spot. The microtiter plates 
were incubated at 4oC for 30 min. Subsequently, excess trypsin solution was removed 
from each gel spot and replaced by approximately 10 µl of 25mM NH4HCO3. The 
microtiter plates were sealed thoroughly and trypsinization was performed for 16 h at 
37oC. 
 
After tryptic digestion, the peptide digest from each gel spot was transferred to 
individual microcentrifuge tubes. Peptide extraction from the gel spots was enhanced 
by the addition of 10 µl of 0.1% (v/v) trifluoroacetic acid (TFA; Sigma) in 50% (v/v) 
ACN to each gel spot and the microtiter plate was sonicated in an ultrasonic water 
bath (Crest Ultrasonics, Trenton, NJ, USA). The resultant peptide digest was 
combined with that obtained initially.  
 
2.3.4.2 Matrix-assisted Laser Desorption/Ionization Tandem Time-of-Flight 
Mass Spectrometry (MALDI-TOF/TOF MS) 
 
The peptide digest from each gel spot was dried using the Speed Vac. 10 µl of 0.1% 
(v/v) TFA in 50% ACN was subsequently added to each peptide digest, which was 
then dried as before. 1 µl of matrix solution (5 mg/ml α-cyano-4-hydroxy-cinnamic 
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acid (Sigma), 0.1% (v/v) TFA, 50% (v/v) ACN and 2% (w/v) ammonium citrate) was 
added to re-suspend each dried digest. The resultant peptide digest solution (~1 µl) 
was then spotted onto a MALDI stainless steel plate and air-dried.  
 
MS and MS/MS spectra were obtained using the ABI 4800 Proteomics Analyzer 
MALDI-TOF/TOF Mass Spectrometer (Applied Biosystems) operating in a result –
dependent acquisition mode. For MS analysis, typically 500 shots were accumulated 
for each well of sample. MS data were automatically obtained with the five most 
intense ions selected for MS/MS. Six external standards (mass standard kit for the 
4700 Proteomics Analyzer calibration mixture, Part Number 4333504, Applied 
Biosystems) were used to calibrate each spectrum to a mass accuracy within 50ppm. 
The  MS/MS analyses were performed using air, at collision energy of 2kV and a 
collision gas pressure ~2 x10 -6 Torr. Stop conditions were implemented so that 2000 
to 3000 shots were accumulated depending on the quality of the spectra. 
 
MASCOT search engine (version 2.1; Matrix Science) was used to search all of the 
tandem mass spectra. GPS ExplorerTM     software Version 3.6 (Applied Biosystems) 
was used to create and search files with MASCOT search engine for peptide and 
protein identification. International Protein Index (IPI) human database Version 3.18 
(Kersey et al., 2004) was used for the search and was restricted to tryptic peptides. N-
terminal acetylation, Cysteine C-terminal carbamidomethylation, and methionine 
oxidation were selected as variable modifications. One missing cleavage was allowed. 
Peptide mass tolerance and fragment mass tolerance were set to 150 ppm and ± 0.4 
Da respectively. Maximum peptide rank was set to 2 and minimum ion score C.I.% 
(peptide) was set to 50. 
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2.4. ANTIGEN VALIDATION WITH COMMERCIAL ANTIBODIES 
 
Antigens that exhibited cancer specificity were identified by mass spectrometry. In 
addition, the identity of the twelve cirrhosis- and HCC-associated autoantigens was 
validated with commercial antibodies. Antibodies against the following proteins were 
probed against 2-D blots of liver tissue lysate: adipophilin (USBiological, 
Massachusetts, USA), poly(rC)-binding protein 1 (Abnova, Taiwan), triosephosphate 
isomerase (Abnova), F-actin capping protein alpha-1 subunit (Abnova), rho GDP-
dissociation inhibitor 2 (Abnova), fumarate hydratase (Abnova), galectin-1 (Abnova), 
stress-70 protein (Lab Vision, Fremont, USA), rho GDP-dissociation inhibitor 1 
(Abnova), heat shock protein 60 (Lab Vision), heat shock cognate 71 kDa protein 
(USBiological), and ES1 protein homolog (Abnova). The immunodetection procedure 
was as for serum analysis (Section 2.6.2). Antibodies against adipophilin, galectin-1 
and stress-70 protein were diluted 1:500; antibodies against fumarate hydratase, heat 
shock cognate 71 kDa protein, and rho GDP-dissociation inhibitor 1, 1:750; 
antibodies against the other 6 proteins, 1:1000. The membranes were incubated with 
either horseradish peroxidase-conjugated anti-mouse (GE Healthcare) or anti-rabbit 
(Pierce) IgG antibodies at a dilution of 1:5000.  
 
The 2-D blots were stripped either once or twice and reprobed with different 
commercial antibodies. The 2-D blots were stripped in 100mM 2-mercaptoethanol 
(Merck), 62.5mM Tris-HCl (pH 6.8), and 2% (w/v) SDS for 45 min at 50 – 60oC with 
periodical shaking. They were then washed four times with TBST with each wash 
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lasting 15 min. Following that, the membranes were blocked overnight and incubated 
with other antibodies as described previously.  
 
2.5. PHOSPHOTYROSINE AND PHOSPHOSERINE DETECTION 
 
Liver tissue lysates were separated by 2-DE and transferred onto membranes. Two 
such blots were incubated overnight at 4oC in 5% (w/v) BSA (Sigma) dissolved in 
TBST. Subsequently, the blots were rinsed with TBST and incubated with anti-
phosphoserine (Calbiochem, San Diego, USA) and anti-phosphotyrosine antibody 
(clone Py20, BD Transduction Lab, Canada) respectively. Anti-phosphoserine 
antibody was diluted 1:200 times with 1% (w/v) BSA in TBST; anti-phosphotyrosine 
antibody, 1:1000 times. After the primary antibody incubation, the blots were 
subjected to four 15-min washes with TBST. The blots were then incubated with their 
respective secondary antibodies for 1 h at room temperature. For phosphoserine 
detection, the secondary antibody used was goat anti-mouse IgM (µ chain specific; 
Pierce) diluted 1:2500 times with 1% (w/v) BSA in TBST. For phosphotyrosine 
detection, the secondary antibody used was rabbit anti-mouse IgG (Sigma) diluted 
1:2000 times. The blots were then washed four times for 10 min each. 
Immunodetection was performed as described previously. 
 
2.6. GLYCOPROTEIN STAINING 
 
Proteins from the moderately differentiated HCC tissue lysate were separated on a 2-
D gel and stained with the Pro-Q Emerald 300 glycoprotein stain (Molecular Probes, 
Invitrogen, Carlsbad, California) to detect glycoproteins in the liver tissue lysate. It 
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was subsequently stained with the SYPRO Ruby total protein stain for comparison 
(Molecular Probes).  
 
The staining procedures were performed as per manufacturer’s instructions. Every 
step was conducted with constant shaking on an orbital shaker. Briefly, the 2-D gel 
was fixed in 200 ml of 50% (v/v) methanol and 5% (v/v) acetic acid for 45 min. Fresh 
fixing solution was then replaced and the gel was fixed overnight. The next day, the 
gel was incubated for 20 min in 500 ml of 3% (v/v) acetic acid before being oxidized 
in 400 ml of oxidizing solution for 1 h. The gel was then subjected to four 20-min 
washes with 500 ml of 3% (v/v) acetic acid. Subsequently the gel was incubated in the 
dark for 2.5 h with 200 ml of diluted Pro-Q Emerald 300 staining solution. The gel 
was washed twice with 500 ml of 3% (v/v) acetic acid; each wash lasted 20 min. The 
gel was rinsed with ultra-pure water before imaging. Stained glycoproteins were 
visualized using a 300 nm UV transilluminator.  
 
The same gel was subsequently subjected to four 5-min washes with 500 ml of ultra-
pure water before being incubated overnight in 330 ml of undiluted SYPRO Ruby 
stain. The gel was washed twice in 200 ml 10% (v/v) methanol and 7% (v/v) acetic 
acid for 15 min each. After rinsing the gel twice with ultra-pure water, the gel was 
imaged on the Typhoon 9410 variable mode imager (GE Healthcare). 
 
2.7. SDS PAGE 
 
For the analysis of HCC tissues, 10µg of each lysate was loaded per well. Prior to 
loading, the samples were denatured by heating at 95oC for 10min in sample buffer 
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consisting of 0.125M Tris-HCl (pH 6.8), 4% SDS, 10% DTT, 10% glycerol (Merck) 
and 0.004% bromophenol blue.  
 
Proteins were concentrated by isotachophoresis as they passed through the 4% 
stacking gel and were resolved after they entered the 10% separating gel. Mini-
Protean III Units (Bio-Rad) were utilized. A constant current of 15mA per gel was 
applied until the tracking dye migrated to within 3mm from the bottom end of the gel. 





















3.1. PRELIMINARY STUDIES 
 
3.1.1. The Feasibility of Using a Single Liver Cancer Tissue as an Antigen Source  
 
In this study, proteins originating from HCC tumour tissues were selected as antigen 
sources. The feasibility of using a single tumour tissue as an antigen source was 
investigated. To this end, one HCC patient serum and one normal serum were probed 
against three different HCC liver tissue lysates. The resulting immunoblots were 
analyzed for HCC-associated autoantibodies that were consistently present 
irrespective of the antigen source used. Figures 3.1 and 3.2 illustrate the experimental 
outline and results for this study respectively. Five antigenic spots representing five 
unique proteins were detected in all three tissue lysates while one antigenic spot was 
detected in two out of three lysates. These results thus suggest that a single liver 
cancer tissue can be used as an antigen source. We have chosen a moderately 












Probed with  
Serum from one normal 
individual 
Serum from one patient with 
poorly differentiated HCC 
Cirrhotic liver tissue lysate 
3                                         10 
Moderately differentiated 
HCC tissue lysate 
3                                       10 
Poorly differentiated HCC 
tissue lysate 
3                                        10 
Compare immunoblots of 
each tissue lysate 
Locate common antigenic spots 
and identify antigens using tandem 
MS 
Compare immunoblots of 
each tissue lysate 
Figure 3.1. Outline of preliminary experiments. The feasibility of using a 
single tumour tissue as an antigen source was investigated. 
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Poorly Differentiated HCC 
Liver Tissue Lysate 
Moderately Differentiated 
HCC Liver Tissue Lysate 
Cirrhotic Liver Tissue 
Lysate 
Figure 3.2. Preliminary Western blot results. Antigenic spots that were found in at least two out of three 2-D blots probed with patient 
serum were circled. Six such spots were found, each circled with a different colour. The identities of these proteins were determined by 






























































































































3.2. THE SEARCH FOR CIRRHOSIS- AND HCC-ASSOCIATED  
       AUTOANTIBODIES 
 
The experimental outline of the SERPA approach used in identifying autoantibodies 
is presented in Figure 3.3. Proteins from the tissue lysate were first resolved in pH 3 – 
10NL IPG strips and then orthogonally separated based on molecular weight in 12.5% 
polyacrylamide gels. Each 2-D gel contained 200µg of proteins. It was either used for 
silver-staining or for western blot analysis.  After the immunostaining step, the blot 
was stained with colloidal silver to visualize the protein spots on the PVDF membrane. 
Immunoreactive spots that were observed on blots probed with patient sera were 
mapped to protein spots on an identical silver-stained 2-D gel.  These protein spots, 
after in-gel tryptic digestion, were then analyzed by tandem MS. Consequently, the 
autoantigens (and their corresponding autoantibodies in sera), associated with liver 
cirrhosis and/or HCC could be identified. In this study, sera from 15 patients and 4 
healthy individuals were analyzed (summarized in Figure 3.4). The results are shown 
in Figures 3.5 to 3.7.  
 
Figure 3.5 (a) shows the blots that were incubated with normal sera whereas Figures 
3.5 (b), (c), and (d) show blots that were incubated with patient sera. Each blot is 
labeled according to the serum it was incubated with. Normal sera are denoted as N1, 
N2, N3, and N4, while patient sera are labeled according to the patient number. The 
clinical characteristics of each patient are listed in Table 2.1. Figure 3.6 illustrates the 
difference in reactivity of each antigen with various sera, while Figure 3.7 shows the 
location of the cirrhosis- and HCC-associated antigens on a silver-stained 2-D gel.  
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As expected, most normal sera gave rise to fewer immunoreactive spots (Figure 3.5). 
The notable exception was serum N4, which had more immunoreactive spots than 
some of the patient sera. Moreover, many of these spots reacted strongly with serum 
N4. With regards to the patient sera, most yielded numerous immunoreactive spots, 
but cirrhotic and poorly differentiated HCC sera generally had more immunoreactive 
spots as compared to moderately differentiated HCC sera.  
 
An immunoreactive spot that was detected in at least three out of the five (60%) 
patient sera at a specific disease stage was considered to be associated with that 
disease stage. On this basis, fourteen cirrhosis- and/or HCC-associated 
immunoreactive spots were found. The locations of these immunoreactive spots on a 
2-D gel are shown in Figure 3.7. Out of these fourteen immunoreactive spots, twelve 
yielded unique protein identities when analyzed by tandem MS (Table 3.1). These 
antigens are listed in Table 3.2 where their association with various disease stages is 
illustrated. Some general biological properties of these antigens are listed in Table 3.3. 
The difference in reactivity of each of these antigens with various sera is shown in 
Figure 3.6. 
 
As a negative control, a similar 2-D blot incubated with only secondary antibody 
(anti-human IgG) showed no immunoreactive spots (Figure 3.8). This indicated that 
any immunoreactivity observed with patient and control sera was not due to reaction 






Identification of immunoreactive proteins via MS/MS and 
database search 
Tumourous liver tissue from one patient with 
moderately differentiated HCC 
Homogenize with Lysis Buffer in 
liquid-nitrogen cooled mortar and 
pestle. Ultracentrifuge. Collect 
supernatant. 
Liver tissue lysate 
Correlation and localization of immunoreactive protein spots 
on the silver-stained 2-D gel 
2-DE 
Western blot Silver Stain Probe membrane 
with patient or 
control serum 
Figure 3.3. Outline of the SERPA approach in identifying cirrhosis-and 
HCC-associated autoantibodies. 





Figure 3.4. Summary of the different types of sera analyzed by the 
SERPA approach. 
2-DE 
Liver tissue lysate from one 
patient with moderately 
differentiated HCC 
5 patients with cirrhosis 
Probe with sera from 
5 patients with moderately 
differentiated HCC 
5 patients with poorly 
differentiated HCC 
4 healthy individuals 
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Figure 3.5. Western blot analysis of 
HCC tissue lysate probed against 
human serum. Immunoreactive spots that 
were commonly elicited in different 
patients are circled. Spots that yielded 
insignificant MS results are labeled with 
an arbitrary spot number. 
 
Abbreviations: PCBP1 – Poly(rC)-binding 
protein 1; TPI – Triosephosphate 
isomerase; CAPZ1 – F-actin capping 
protein alpha-1 subunit; RhoGDI2 – Rho 
GDP-dissociation inhibitor 2; FH – 
Fumarate hydratase; RhoGDI1 – Rho 
GDP-dissociation inhibitor 1; HSP60 – 
Heat shock protein 60; HSC70 – Heat 




Figure 3.5 (a). Moderately differentiated HCC tissue lysate probed with serum from normal individuals. 
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Figure 3.5 (b). Moderately differentiated HCC tissue lysate probed with serum from patients with cirrhosis. 
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Figure 3.5 (c). Moderately differentiated HCC tissue lysate probed with serum from patients with moderately differentiated HCC. 
  65 
 
Figure 3.5 (d). Moderately differentiated HCC tissue lysate probed with serum from patients with poorly differentiated HCC. 
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Figure 3.6. A comparison of the immunoreactivity of each autoantigen with 
patient and normal sera.  
Row labeled ‘Gel’ – Silver-stained images of the respective protein spots;  
Row labeled ‘Validation by Western blot’ – Identification of spots by the respective 
commercial antibodies;  
Rows labeled ‘Patient 1 to 5’ – Protein spots that reacted with cirrhotic serum; 
Rows labeled ‘Patient 6 to 10’ – Protein spots that reacted with moderately differentiated 
HCC serum; 
Rows labeled ‘Patient 11 to 15’ – Protein spots that reacted with poorly differentiated HCC 
serum; 
Rows labeled ‘N1 to N4’ – Protein spots that reacted with normal serum; 
Blank spaces – Indicates a lack of reactivity between serum and protein. 
 
Figure 3.6 (a). Immunoreactivity profiles of adipophilin, PCBP1, TPI, CAPZ1, 





Figure 3.6 (b). Immunoreactivity profiles of galectin-1, mortalin, 
RhoGDI1, HSP60, HSC70 and ES1. 
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Figure 3.7. Location of cirrhosis- and HCC-specific antigens on a silver-
stained 2-D gel. Antigens were circled with different colours to signify the 
particular disease stage. Antigens 3915 and 3931 could not be identified by 
MALDI tandem MS.  
 
Abbreviations: PCBP1 – Poly(rC)-binding protein 1; TPI – Triosephosphate 
isomerase; CAPZ1 – F-actin capping protein alpha-1 subunit; RhoGDI2 – Rho 
GDP-dissociation inhibitor 2; FH – Fumarate hydratase; RhoGDI1 – Rho GDP-
dissociation inhibitor 1; HSP60 – Heat shock protein 60; HSC70 – Heat shock 























































Figure 3.8.  
Moderately differentiated HCC tissue lysate probed only with secondary 
antibody (anti-human IgG). This is a negative control to show that the 
immunoreactivity observed in Figure 3.5 is due to reaction with patient or control 
sera.  
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TABLE 3.1. MS/MS data of the 12 immunoreactive spots. 
 
IPI 
















          
IPI00293307 Adipophilin 71% 2 15 ASVAVDPQPSVVTR 379 100 239 100 
   204 219 KVEGFDLVQKPSYYVR     
   246 264 SQQTISQLHSTVHLIEFAR     
          
IPI00016610 50% 1 17 MDAGVTESGLNVTLTIR 236 100 191 100 
 
Poly(rC)-binding 
protein 1 (PCBP1) 
 326 346 QVTITGSAASISLAQYLINAR     
          
IPI00465028 74% 211 223 TATPQQAQEVHEK 472 100 346 100 
  121 134 DCGATWVVLGHSER     




 255 283 ELASQPDVDGFLVGGAS LKPEFVDIINAK     
          
IPI00005969 50% 37 46 LLLNNDNLLR 153 100 116 100 
 
F-actin capping protein 
alpha-1 subunit 
(CAPZ1)  19 36 FITHAPPGEFNEVFNDVR     
          
IPI00003817 73% 124 130 YVQHTYR 131 100 76 100 
 
Rho GDP-dissociation 
inhibitor 2 (RhoGDI2) 
 63 70 APNVVVTR     
          




 422 444 LLGDASVSFTENCVVGIQ ANTER     
          
IPI00219219 88% 1 18 ACGLVASNLNLKPGECLR 240 100 173 100 
 
Galectin1 
 37 48 DSNNLCLHFNPR     
  71 
IPI 
















          
IPI00007765 Mortalin 59% 349 360 AQFEGIVTDLIR 367 100 152 100 
   499 513 LLGQFTLIGIPPAPR     
          
IPI00003815 Rho GDP-dissociation inhibitor 1 (RhoGDI1) 39% 127 133 YIQHTYR 70 99.464 36 97.724 
          
IPI00472102 60% 432 448 AAVEEGIVLGGGCALLR 426 100 285 100 
 
Heat shock protein 60 
(HSP60) 
 271 292 KPLVIIAEDVDGEALSTLVLNR     
          
IPI00003865 52% 300 311 ARFEELNADLFR 256 100 135 100 
 
Heat shock cognate 71 
kDa protein (HSC70) 
 138 155 TVTNAVVTVPAYFNDSQR     
          
IPI00024913 68% 117 141 ITDLANLSAANHDAAIFPG GFGAAK 225 100 157 100 
 
ES1 protein homolog 
(ES1) 
 45 72 VALVLSGCGVYDGTEIHE ASAILVHLSR     













Table 3.2. Summary of the Autoantibodies against the listed autoantigens. A ‘+’ 
represents immune reactivity in one patient. An antigen that was found in at least 3 
out of the 5 patients (60%) who were at a specific disease stage was considered to be 
associated with that disease stage. For instance, adipophilin was associated with 
cirrhosis only, whereas TPI was associated with cirrhosis and moderately 
differentiated HCC.  
 
Abbreviations: PCBP1 – Poly(rC)-binding protein 1; TPI – Triosephosphate 
isomerase; CAPZ1 – F-actin capping protein alpha-1 subunit; RhoGDI2 – Rho GDP-
dissociation inhibitor 2; FH – Fumarate hydratase; RhoGDI1 – Rho GDP-
dissociation inhibitor 1; HSP60 – Heat shock protein 60; HSC70 – Heat shock 




Antigen Cirrhosis Mod Diff HCC Poorly Diff HCC Normal 
Adipophilin +++  +  
PCBP1 +++++ ++ + + 
TPI +++ +++ ++ ++ 
CAPZ1 +++ +++ +++  
RhoGDI2 +++ +++++ +++++ ++ 
FH +++++ ++++ +++  
Galectin1 ++ +++ +++ ++ 
Mortalin  +++ ++  
RhoGDI1  +++ + + 
HSP60 ++ + ++++ + 
HSC70 + + ++++ + 
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Thr MW / 
Expt MW 
(kDa) 
Thr pI / 
Expt pI Functions References 
IPI00293307 Adipophilin Membrane 48 / 53.8 6.34 / 6.86 - marker of lipid accumulation 
- expressed in a wide range of lipid accumulating cells, 
including fatty change hepatocytes in alcoholic liver cirrhosis 
- function is not well defined 
- believed to be involved in lipid homeostasis of adipocytes 
and macrophages 
- during fasting, believed to coat newly synthesized 
triacylglycerol-containing lipid droplets in the liver  
Dalen et al., 2006; 
Heid et al., 1998  
 
       
IPI00016610 PCBP1 Nucleus / 
Cytoplasm 
37.5 / 42.9 6.66 /  7.46 - single-stranded nucleic acid binding protein that binds 
preferentially to oligo deoxycytosines (dC) 
- can interact with and activate the c-myc IRES (internal 
ribosome entry segment)  
Evans et al., 2003 
 
       
IPI00465028 TPI Mainly cytoplasm 26.5 / 27.5 6.51 / 7.42 - catalyzes the conversion of D-glyceraldehyde 3-phosphate 
to glycerone phosphate 
Orosz and Ovadi, 
1986 
       
IPI00005969 CAPZ1 Cytoplasm 32.8 / 36.8 5.45 / 5.25 - binds to the fast growing ends of actin filaments in a 
calcium-independent manner, blocking the exchange of actin 
subunits at these ends.  
- CAPZ1 does not sever actin filaments 
Casella and 
Torres, 1994 
       
IPI00003817 RhoGDI2 Cytoplasm 22.9 / 27.1 5.10 / 4.69 - regulates the GDP/GTP exchange reaction of the Rho 
proteins by inhibiting the dissociation of GDP from them, 
and the subsequent binding of GTP to them 
Sasaki and Takai, 
1998 
       
IPI00296053 FH Mitochondria 54.6 / 48.8 8.85 / 8.12 - catalyzes the conversion of fumarate to malate in the 
tricarboxylic acid (TCA) cycle 
- may act as a tumour suppressor 
Pollard et al., 
2003 
       







Thr MW / 
Expt MW 
(kDa) 
Thr pI / 
Expt pI Functions References 
IPI00219219 Galectin1 Mainly 
cytoplasm; 
extracellular side 
of cell membrane 
14.6 / 14.4 5.34 / 4.50 - may regulate cell apoptosis and cell differentiation 
- may cause cell aggregation, cell adhesion, and induce 
membrane redistribution 
- has a multitude of binding partners including beta-
galactoside, CD45, CD3 and CD4 
- involved in the initiation amplification, and resolution of 
inflammatory responses 
Camby et al., 
2006 
       
IPI00007765 Mortalin Mitochondria 73.7 / 77.3 5.87 / 5.30 - belongs to the HSP70 family 
- inhibits cell division 
- implicated in the control of cell proliferation, 
tumourigenesis, and cellular aging 
- may act as a chaperone 
- influences the Ras-Raf-MAPK pathway by modulating the 
prenylation and stability of Ras 
- consistently over-expressed in colorectal cancer with high 
levels of expressions correlating with poor prognosis 
Dundas et al., 
2005; Takashima 
et al., 2003 
       
IPI00003815 RhoGDI1 Cytoplasm 23.1 / 27.7 5.03 / 4.42 - regulates the GDP/GTP exchange reaction of the Rho 
proteins by inhibiting the dissociation of GDP from them, 
and the subsequent binding of GTP to them 
Sasaki and Takai, 
1998 
       
IPI00472102 HSP60 Mitochondria 61.1 / 68.2 5.70 / 5.06 - implicated in mitochondrial protein import and 
macromolecular assembly 
- facilitate correct folding of imported proteins 
- prevent mis-folding and promote re-folding and proper 
assembly of unfolded polypeptides generated under stress 





       
       
       







Thr MW / 
Expt MW 
(kDa) 
Thr pI / Expt 
pI Functions References 
IPI00003865 HSC70 Cytoplasm 70.9 / 77.3 5.37 / 5.16 -belongs to the HSP70 family 
- constitutively expressed chaperone that is inducible by heat 
shock stress 
- translocates rapidly from the cytoplasm to the nuclei, and 
especially to the nucleoli, upon heat shock 
- binds to nascent polypeptides to facilitate correct folding 
- participates in the formation and repair of higher order 
protein structures such as that of ATPase 
Takashima et al., 
2003 
       
IPI00024913 ES1 Likely 
mitochondria 
28.1 / 26.3 8.5 / 7.78 - function unknown 
- contains a potential targeting sequence to mitochondria in 
its N terminal region 
- shows significant homology with the zebrafish ES1 protein 
and Escherichia coli SCRP-27A/ELBB proteins 
- based on sequence alignment, belongs to the DJ-1/PfpI 
family 
- found to be upregulated in fetal Down syndrome brains  
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TABLE 3.4. MS/MS data of proteins that reacted with normal and patient sera. 
 
IPI 

















          
IPI00022463 63% 531 541 EGYYGYTGAFR 353 100 113 100 
 
Serotransferrin precursor 
 588 600 KPVEEYANCHLAR     
          
IPI00745872 56% 348 360 DVFLGMFLYEYAR 276 100 144 100 
 
Serum albumin precursor 
 509 524 RPCFSALEVDETYVPK     
          
IPI00554648 64% 381 391 LALDIEIATYR 484 100 281 100 
  213 224 LEGLTDEINFLR     
  198 212 DVDEAYMNKVELESR     
 
Keratin, type II cytoskeletal 8 
 133 147 SNMDNMFESYINNLR     
          
IPI00465248 66% 240 253 VVIGMDVAASEFFR 306 100 198 100 
 
Enolase 1 
 33 50 AAVPSGASTGIYEALELR     
          
IPI00554788 54% 261 268 AQYDELAR 253 100 98 100 
 
Keratin, type I cytoskeletal 
18 
 138 149 AQIFANTVDNAR     
          
IPI00220301 71% 97 105 LPFPIIDDR 235 100 123 100 
 
Peroxiredoxin-6 
 41 52 DFTPVCTTELGR     
          
IPI00215983 61% 81 89 GGPFSDSYR 210 100 135 100 
 
Carbonic anhydrase 1 
 214 227 ESISVSSEQLAQFR     
          
IPI00022314 72% 195 202 NVRPDYLK 210 100 117 100 
 
Superoxide dismutase [Mn], 
mitochondrial precursor 





3.3. ANTIGEN VALIDATION WITH COMMERCIAL ANTIBODIES 
 
 As an independent verification of the protein identities, 2-D blots of the moderately 
differentiated HCC liver tissue lysate were incubated with commercial antibodies 
specific for each of the twelve autoantigens. The results are shown in Figure 3.9. It 
was apparent that all of the commercial antibodies gave positive reactions with 
protein spots that had the same position on the 2-D blots as their respective 
immunoreactive spots. This confirmed the protein identities of the spots as obtained 
by tandem MS.  
 
Some of the commercial antibodies gave rise to one immunoreactive spot but some 
yielded more than one immunoreactive spots. As a negative control, a 2-D blot was 
incubated with secondary antibody (anti-mouse IgG) only (Figure 3.9 (e)). Many 
immunoreactive spots were observed. Notably, these non-specific immunoreactive 
spots were observed in some of the other blots in Figure 3.9, signifying that some of 

















Figure 3.9. Antigen validation with Western blot using commercial 
antibodies. The identity of the 12 antigens that exhibited cancer specificity was 
validated with commercial antibodies. Antibodies against the antigens were 
probed against 2-D blots of moderately differentiated HCC liver tissue lysate. 
The specific immunoreactive spots are circled in blue. The silver-stained 2-D gel 
from Figure 3.9 is displayed so that the relative 2-D positions of the 
immunoreactive spots of interest and the immunoreactive spots resulting from the 
commercial antibodies can be correlated. 
 
Figure 3.9 (a).  
Moderately differentiated HCC tissue lysate probed respectively with anti-




Figure 3.9  (b).  
Moderately differentiated HCC tissue lysate probed respectively with anti-




Figure 3.9  (c).  
Moderately differentiated HCC tissue lysate probed respectively with anti-





Figure 3.9 (d).  
Moderately differentiated HCC tissue lysate probed respectively with anti-
CAPZ1 and anti-Galectin1. 
  
Figure 3.9 (e).  
Moderately differentiated HCC 
tissue lysate probed only with 




3.4. THE SEARCH FOR POST-TRANSLATONAL MODIFICATIONS IN THE 
CIRRHOSIS- AND HCC-ASSOCIATED AUTOANTIGENS 
 
3.4.1. The Search for Phosphorylated Autoantigens 
 
To investigate whether any of the twelve autoantigens were phosphorylated, 2-D blots 
of moderately differentiated HCC tissue lysate were probed with anti-phosphoserine 
and anti-phosphotyrosine antibodies (Figure 3.10) respectively. Our results showed 
that only RhoGDI1, HSC70 and HSP60 were phosphorylated. Since HSC70 and 
HSP60 are phosphoproteins (Uniprot), this result is a validation of our experimental 
protocol, and can thus serve as a positive control.  
 
3.4.2. The Search for Glycosylated Autoantigens  
 
In this experiment, a 2-D gel of the moderately differentiated HCC tissue lysate was 
incubated with the Pro-Q Emerald glycoprotein stain (Figure 3.11). This fluorescent 
stain is a specific stain for glycoproteins. After obtaining an image of the fluorescent 
stain, the 2-D gel was subsequently stained with Sypro Ruby to reveal all the proteins 
in the gel. The fluorescent signals from the glycoprotein stain were found to be very 
weak and could not be improved. Background noise was also high, thus resulting in a 
low signal to noise ratio. Nevertheless three glycosylated spots were found: two of 
which were found to be isoforms of albumin and serotransferrin precursor 
respectively by tandem MS. Albumin (Uniprot accession number: P02768) and 
serotransferrin (Uniprot accession number: P02787) are known glycoproteins, so they 
can serve as positive controls for the glycoprotein stain. Thus, none of the 
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autoantigens   appeared to be glycosylated, but this could be due to the low sensitivity 
of the Pro-Q Emerald glycoprotein stain as well as the low abundance of any 








HCC tissue lysate probed with anti-phosphoserine and anti-phosphotyrosine 
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Figure 3.11. 
2-D gels of HCC tissue lysate stained first with Pro-Q Emerald glycoprotein stain, then with Sypro Ruby total protein stain. The 
glycosylated proteins are circled in red and those identified are labeled. None of the cirrhosis- and HCC-associated autoantigens were 
found to be glycosylated. Glycosylated proteins that were not the antigens of interest were not analyzed. 





3.5. THE SEARCH FOR DIFFERENTIALLY-REGULATED 
AUTOANTIGENS  
 
Self-proteins that were differentially regulated in cancer cells could prime the immune 
system to mount a humoral response (Anderson and LaBaer, 2005). Figures 3.12 (a) 
and (b) show the expression levels of the autoantigens in moderately and poorly 
differentiated HCC tissue lysates respectively.  The immunoblots were also stained 
with colloidal silver to check for consistency in the protein loading in the 2D gel. 
Differences in regulation were evaluated by comparing the relative expression levels 
of a protein in the tumourous and non-tumourous regions of liver tissue from a single 
patient.  
 
 The autoantigen was only deemed to be differentially regulated in moderately 
differentiated HCC if it was regulated similarly in at least 3 out of 5 tissue pairs 
(Figure 3.12 (a)). For poorly differentiated HCC, the autoantigen had to be regulated 
similarly in at least 4 out of 7 tissue pairs (Figure 3.12 (b)).  
 
From the results, FH and ES1 were found to be down-regulated, but GAL up-
regulated in both moderately and poorly differentiated HCC. TPI and RhoGDI1, on 
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Figure 3.12 (a). 
Expression levels of Cirrhosis- and HCC-associated Autoantigens in Moderately differentiated HCC tissue lysates. Proteins (10µg) 
from 5 pairs of moderately differentiated HCC tissue lysates were separated via SDS PAGE, transferred onto membranes, and probed with 
commercial antibodies against the indicated antigens of interest. Each pair comprised of tissue from the non-tumourous (N) and tumourous 
(T) regions of the liver of one patient with moderately differentiated HCC.  











No consistent trend 
No consistent trend 
No consistent trend 
No consistent trend 
↓ 
↑ 
No consistent trend 
No consistent trend 
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   N     T     N     T     N    T     N     T     N     T                 
ES1 ↓ 
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Figure 3.12 (b). 
Expression levels of Cirrhosis- and HCC-associated Autoantigens in Poorly differentiated HCC tissue lysates. Proteins (10µg) from 7 
pairs of poorly differentiated HCC tissue lysates were separated via SDS PAGE, transferred onto membranes, and probed with commercial 
antibodies against the indicated antigens of interest. Each pair comprised of tissue from the non-tumourous (N) and tumourous (T) regions of 
the liver of one patient with poorly differentiated HCC.  
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HCC is an asymptomatic cancer with high morbidity and mortality rates (Usatoff and 
Habib, 2002). Autoantibodies that are detectable in early-stage HCC are promising 
biomarkers that enable early diagnosis (Le Naour et al., 2002). In this study, a SERPA 
approach is used to identify such autoantibodies.  
 
4.1. PRELIMINARY STUDIES 
 
4.1.1. A Single Liver Cancer Tissue as the Antigen Source 
 
In our study, the identification of HCC-associated autoantibodies depends on the 
antigen source that the sera are probed against. Autoantibodies that do not have 
corresponding TAAs in the antigen source will not be identified, even if they are 
HCC-associated. Consequently, it is imperative to select an appropriate antigen source 
that closely reflects the HCC proteome. 
 
The antigen source can be a whole lysate from either a cell line or tumour tissue. 
Many studies have reported the use of cell lines as antigen sources (Le Naour et al., 
2002; Nakanishi et al., 2006), but recent studies have also used tumour tissues (Cui et 
al., 2005; Takashima et al., 2006; Yang et al., 2007). While there are advantages in 
using cell lines, tumour tissues are preferable because they are obtained directly from 
the patients and so, are likely to possess protein profiles that are more reflective of the 
cancer. However, tissue samples are known for their heterogeneities. Samples from 
different patients may contain different cell types and may also be contaminated, to 
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various extents, by proteins present in blood (Alaiya et al., 2005). This heterogeneity 
complicates the comparison of immunoreactive profiles and can potentially prohibit 
the use of a single tumour tissue as an antigen source.  Thus some investigators have 
adopted autologous samples for screening (Cui et al., 2005), but this approach is 
rather laborious and hence not amenable to high throughput SERPA.  
 
Thus, in this study, the feasibility of using a single tumour tissue as an antigen source 
but using different sera for immunostaining was explored. Besides increasing the 
throughput, it was hoped that it would result in the establishment of a standardized 
platform such that any differences in the immunoreactive profiles would be attributed 
to the differences in sera and not the antigen source.  
 
In this experiment, when HCC tissues from three patients were probed  with the same 
serum (Figure 3.2), five HCC-associated autoantibodies were consistently identified 
from the immunoreactive profiles of the three tissues. . This result clearly established 
that it is feasible to use a single antigen source for SERPA.  
 
4.2. THE SEARCH FOR CIRRHOSIS- AND HCC-ASSOCIATED 
AUTOANTIBODIES 
 
4.2.1. Reliability of Protein Identities 
 
Table 3.1 and Table 3.4 present the MS/MS data of the cirrhosis- and HCC-associated 
immunoreactive spots and non-specific immunoreactive spots respectively. Protein 
scores that were greater than 60 were considered significant (p<0.05) (Loo, 2003). 
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Notably, the protein candidates listed in Table 3.1 and 3.4 had protein scores of at 
least 70 and most of them had scores of 200 and above. These protein candidates also 
had high total ion scores. Based on these results, we can conclude that the protein 
identities yielded by tandem MS were likely to be reliable. In addition, the protein 
identities of the twelve cirrhosis- and HCC-associated immunoreactive spots were 
independently verified with commercial antibodies. Thus we are confident that these 
identities of the immunoreactive spots are correct. 
 
4.2.2. Cirrhosis- and HCC-associated Autoantibodies 
 
Cirrhosis is considered the most significant risk factor for the development of HCC 
(Colombo and Sangiovanni, 2003). Consequently, biomarkers that allow early 
detection of cirrhosis would enable the identification of individuals who are at high 
risk of developing HCC. Currently, there is no effective serum biomarker that enables 
the early detection of cirrhosis. Diagnosis can be confirmed only by liver biopsy and 
cirrhosis cannot be detected readily by ultrasound (Crawford, 2002). In this study, we 
are interested in identifying autoantibodies in serum that can lead to early detection of 
cirrhosis and HCC.   
 
4.2.2.1. The TAA Panel 
 
Twelve cirrhosis- and/or HCC-associated autoantigens were identified in this study 
(Table 3.1). Interestingly, several of these autoantigens were found to be associated 
with different stages of HCC rather than uniquely with one type of HCC (see Table 
3.2). These findings implied that a panel of TAAs comprising six out of the twelve 
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autoantigens would facilitate early detection and risk stratification of HCC (see Table 
4.1).  
 
These six autoantigens were chosen because (i) they were each associated with one 
HCC stage and (ii) together, they covered the three stages of HCC investigated in this 
study. Thus these six autoantigens would enable risk stratification and the detection of 
early HCC. To illustrate, an individual whose serum reacted only with adipophilin and 
PCBP1 when probed against the TAA panel likely suffered from cirrhosis, but had not 
developed HCC yet. Similarly, sera from patients with moderately differentiated HCC 
would react with Mortalin, and RhoGDI1 only whereas sera of patients with poorly 
differentiated HCC would react with HSP60 and HSC70. Hence, the proposed TAA 
panel allowed the classification of HCC patients into three groups: (1) those with 
cirrhosis but not HCC, (2) those with moderately differentiated HCC, and (3) those 
with poorly differentiated HCC. Notably, only patients from group 1 and some from 
group 2 would be considered to have early-stage HCC; cirrhosis is considered to be a 
pre-neoplastic stage that precedes HCC (Crawford, 2002). Patients from group 3 
would most likely be considered to have late-stage HCC. In terms of risk stratification, 
individuals with no seroreactivity against the TAA panel would have a low risk of 
developing HCC, but Group 1 patients would have a high risk of developing HCC. 
Our results would be of great significance after successful validation against a larger 








Table 4.1. Autoantigens that make up a TAA panel that enable early detection of 
HCC as well as risk stratification of HCC patients. 
 
Abbreviations: PCBP1 – Poly(rC)-binding protein 1; RhoGDI1 – Rho GDP-
dissociation inhibitor 1; HSP60 – Heat shock protein 60; HSC70 – Heat shock 




Antigen Cirrhosis Mod Diff HCC Poorly Diff HCC Normal 
Adipophilin +++  +  
PCBP1 +++++ ++ + + 
Mortalin  +++ ++  
RhoGDI1  +++ + + 
HSP60 ++ + ++++ + 





4.2.2.2. The TAA Panel: Criteria for a Screening Test 
 
Etzioni et al. (2003) identified four requirements that a screening test should fulfill 
(Table 4.2). Our TAA panel could satisfy only the second and fourth criteria for a 
screening test. The third criterion presumably refers to the differentiation of benign 
and malignant tumours. At present, our TAA panel is unable to distinguish this since 
this would require an analysis with sera from patients with benign liver lesions   but 
this is impeded by the paucity of test samples for our present work. 
  
Tests involving a single biomarker seldom achieve optimal sensitivity or specificity. 
Indeed, the hope that a single biomarker exists that can satisfy the criteria of a 
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screening test is increasingly being regarded as unrealistic (Omenn, 2006; Zolg, 2006). 
In contrast, a panel of biomarkers can yield higher specificity and sensitivity rates, 
even when its individual biomarkers are not as specific or sensitive (Section 1.2.4). 
Our TAA panel is thus in line with this new expectation of modern biomarkers.  
 
Table 4.2. Criteria for Screening Tests. (Adapted from Etzioni et al, 2003) 
 
1. Healthy individuals should be distinguished from cancer patients with a high 
degree of accuracy  
 
 Tests should have high sensitivity and specificity rates 
 Tests should have low false-negative and false-positive rates 
 
2. Detection should be possible before the disease progresses to an advanced stage 
 
 Diagnosis is made while effective treatment is still available             
 
3. Differentiation should be made between lesions that are aggressive, requiring 
treatment, and those that will ultimately do no harm, avoiding the problem of 
over-diagnosis 
 
4. Tests should be inexpensive and well-accepted by the screening population 
 




4.2.2.3. The Autoantigens: Overlap with Other HCC Studies 
 
There are already two established HCC-associated autoantigens, viz.,  p53 and p62 
that have been reported in the literature (Lu et al., 2001; Raedle et al., 1998; Soussi, 
2000; Zhang and Chan, 2002). Unfortunately, these two autoantigens were not 
detected in this study. We have no explanation for this at present, but it may be 
because their levels are beyond the limit of detection using SERPA or the methods 
used for their identification are different.  This latter suggestion is supported by the 
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observation that  none of our twelve autoantigens had been found in HCC  using 
SEREX (Stenner-Liewen et al., 2000; Uemura et al., 2003; Wang et al., 2002; Zhang 
et al., 2001; Zhou et al., 2005), but some overlaps with HCC studies were found using 
the SERPA approach. For example, Le Naour et al. (2002) found autoantibodies 
against HSP60 in 14% of the HCC patients while Takashima et al. (2006) reported 
autoantibodies against superoxide dismutase and peroxiredoxin-6 in HCC patients. In 
our study, these two latter autoantigens were found to be non-specific, and hence were 
not included in our TAA panel.  
 
However, it must be cautioned that it is not ALWAYS true that the same 
autoantibodies would be identified when the same experimental technique was 
employed. This was borne out by several recent reports (Cui et al., 2005; Le Naour et 
al., 2001; Le Naour et al., 2002; Stenner-Liewen et al., 2000; Takashima et al., 2002; 
Takashima et al., 2006; Uemura et al., 2003; Yang et al., 2007; Zou et al., 2005). 
Thus extensive validation with a very large pool of normal and patient sera to confirm 
the list of specific autoantigens is required before the panel can be accepted as 
biomarkers that can be used in the clinics for any cancer, including HCC.  
 
4.2.2.4. Biological Properties of the Autoantigens  
 
It is not known why certain self-proteins could elicit the humoral immune response. It 
could be that these proteins possessed some biological properties that rendered them 
immunogenic. Such properties include the proteins’ subcellular localization, function, 
the presence of post-translational modifications, and differential regulation.  Hence 
proteins that are membrane-bound or secreted (e.g. adipophilin), that serve 
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immunomodulatory roles (e.g. heat shock proteins and galectin1), that are 
glycosylated or phosphorylated (e.g. RhoGDI1), and those that are differentially 
regulated (e.g. TPI, FH, and galectin1) had a higher chance of activating the humoral 
immune system.  
 
In addition, it has been proposed that proteins of high abundance are immunogenic. In 
this study, some cirrhosis- and HCC-associated autoantigens, unlike the non-specific 
autoantigens, were of relatively low abundance. Examples of these are adipophilin, 
PCBP1, CAPZ1, and RhoGDI1. Some autoantigens – HSP60, FH, TPI, and galectin1 
– were of high abundance that was comparable to that of the non-specific 
autoantigens. Hence high abundance might not be an absolute pre-requisite for the 
production of autoantibodies (Anderson and LaBaer, 2005; Caron et al., 2007; 
Casiano et al., 2006).  
 
Consequently, by examining some of the biological properties of the autoantigens 
identified in this study, we could better understand how the autoantigens triggered the 
production of autoantibodies.  The general properties of these autoantigens are listed 
in Table 3.3. 
 
We will proceed to discuss the twelve cirrhosis- and HCC-associated autoantigens. 
Three of them are involved in signaling; three are chaperones; two are enzymes, one 





4.2.2.4.1. Proteins Involved in Signaling 
 
Three of the autoantigens are involved in signaling. They are galectin1, RhoGDI1 and 
RhoGDI2. Thus far, none of them are known to be HCC-associated autoantigens. 
However, autoantibodies against galectin1 and RhoGDI2 have been reported in 
previous studies (Camby et al., 2006; Cui et al., 2005).  
 
Galectin 1 
As can be deduced from Table 3.3, galectin1 is a multi-functional protein. Camby et 
al. (2006) provided a comprehensive review of the myriad functions of galectin1. 
Autoantibodies against galectin1 have been reported in patients with autoimmune and 
infectious uveitis as well as in patients with neurological disorders such as multiple 
sclerosis (Lutomski et al., 1997; Romero et al., 2006). The presence of such 
autoantibodies is thought to indicate impairment of the immunoregulatory system 
because galectin1 is an immunomodulator (Camby et al., 2006; Lutomski et al., 1997). 
 
Strikingly, the over-expression of galectin1 is associated with tumour immune escape 
because galectin1 can suppress T-cell activation and induce T-cell death. Galectin1 is 
also thought to promote tumour progression through its involvement in tumour 
angiogenesis (Camby et al., 2006). In this study, galectin1 was found to be over-
expressed in moderately and poorly differentiated HCC tumour tissues (Figure 3.12). 
At the same time, as an autoantigen, galectin1 was deemed to be associated with 
moderately and poorly differentiated HCC (Table 3.2). The link between these two 
results was intriguing. One possible hypothesis would be that galectin1 was over-
expressed in liver cancer cells to evade attacks from the immune system, and this 
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over-expression of the protein, together with its presence on the cell surface, played a 
part in triggering the humoral immune response. Notably, galectin1 normally 
suppresses T-cell activities, and so, as mentioned earlier, the presence of 
autoantibodies against galectin1 likely reflects an impairment of the 
immunoregulatory system. 
 
RhoGDI1 and RhoGDI2 
 RhoGDI1 and RhoGDI2 are thought to perform similar functions although their 
amino acid sequences were only 66% similar (Clustal W results not shown). However, 
RhoGDI1 was associated with moderately differentiated HCC whereas RhoGDI2 was 
associated with cirrhosis and HCC (Table 3.2).  
 
In this study, RhoGDI1 was found to be over-expressed in poorly differentiated HCC 
(Figure 3.12). Li et al. (2005) similarly reported the over-expression of RhoGDI1 in 
HBV-associated HCC. RhoGDI1 is also over-expressed in ovarian and lung 
metastatic cell lines (Jiang et al., 2003). Notably, autoantibodies against RhoGDI1 
were found predominately in patients with moderately differentiated HCC (Table 3.2). 
It is not known how RhoGDI1 triggers the humoral immune response, but it could be 
due to cancer-associated changes in protein levels or post-translational modifications. 
For instance, from our results, RhoGDI1 was found to be phosphorylated as well 
(Figure 3.10). 
 
RhoGDI2 has been associated with acute leukemia as an autoantigen (Cui et al., 
2005). The exact mechanism of how RhoGDI2 activates the humoral immune system 





Three of the autoantigens – HSP60, HSC70, and mortalin – are chaperones (Table 
3.3). HSP60 and HSC70 are known autoantigens.  
 
HSP60 and HSC70 
In this study, both HSP60 and HSC70 were found to be associated with poorly 
differentiated HCC (Table 3.2). Autoantibodies against these two proteins have been 
detected in autoimmune diseases such as chronic hepatitis and rheumatoid arthritis as 
well as in lung cancer (Fukuda et al., 2004; Shingai et al., 1995; Yang et al., 2007). 
Autoantibodies against HSP60 have also been associated with HCC (Le Naour et al., 
2002). Several hypotheses have been proposed to explain how heat shock proteins 
activate the humoral immune system. Heat shock proteins, including HSP60 and 
HSC70, are immunomodulators that activate antigen presenting cells by binding to 
their cell surface receptors (Li, 2003). Li (2003) proposed that heat shock proteins are 
themselves not immunogenic, but are immunomodulators which can bind to tumour-
associated antigenic peptides. The mechanism causing the production of 
autoantibodies against HSP60 and HSC70 in HCC is unknown. Interestingly, these 
HSP60 and HSP70 have been found to bind to HBx (Section 1.1.5.2), which is known 
to trigger host immune responses (Zhang et al., 2005a). Whether this interaction was 
responsible for the induction of autoantibodies against HSP60 and possibly, HSC70, 
in HBV-associated HCC remains to be investigated. 
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On another note, proteins with increased expression levels have been known to elicit 
responses from the humoral immune system (Anderson and LaBaer, 2005). HSP60 
and HSP70 have been found to be over-expressed in the early phase of liver 
regeneration (Shi et al., 2007). Since uncontrolled liver regeneration can lead to HCC 
development (Crawford, 2002), it was possible that these proteins were also over-
expressed in HCC. Indeed, heat shock proteins such as HSP60 and HSC70 are 
reported to be over-expressed in HCC (Lim et al., 2002; Lim et al., 2005; Luk et al., 
2006; Takashima et al., 2003). Unfortunately, in this study, no consistent trend of 




From Table 3.2, mortalin was found to be associated with moderately differentiated 
HCC. To our knowledge, autoantibodies against mortalin have not been reported. 
Hence, this is the first report that autoantibodies against mortalin were found in 
association with HCC.  Mortalin functions as a chaperone and is part of the heat shock 
70 protein family. However, it has other functions, and is associated with 
carcinogenesis, especially the development of colorectal cancer (Dundas et al., 2005). 
There lies a possibility that mortalin’s myriad functional roles contributed to the 
generation of anti-mortalin autoantibodies. Even though Figure 3.12 indicated that the 
expression of mortalin was not consistently differentially regulated in our tumour 
samples, two groups of researchers have reported that mortalin is over-expressed in 
HCC (Li et al., 2005; Takashima et al., 2003). Thus mortalin could have become 
immunogenic due to its over-expression in HCC tissues. However, this cannot be the 
only explanation, because mortalin is also up-regulated in colorectal cancer and thus 
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far, antibodies against mortalin have not been reported in colorectal cancer patients 




Two of the autoantigens, namely TPI and FH, are enzymes that are present 
ubiquitously in cells (Table 3.3). Autoantibodies against TPI have been found in 
association with HCC, as well as other malignancies and autoimmune diseases 
(Nakanishi et al., 2006; Watanabe et al., 2004; Xiang et al., 2004; Yang et al., 2007). 
FH is not a known autoantigen.  
 
TPI and FH 
From Table 3.2, TPI was associated with cirrhosis and moderately differentiated HCC. 
However, Figure 3.12 showed that TPI was up-regulated in poorly differentiated HCC. 
Together, these results suggested that, in our study, autoantibodies against TPI were 
not produced as a result of the over-expression of TPI. Yet, it should be noted that TPI 
is commonly found to be up-regulated in lung cancer and HCC, and autoantibodies 
against TPI have been associated with these two malignancies (Chen et al., 2002b; 
Nakanishi et al., 2006; Lee et al., 2005; Yang et al., 2007). The connection between 
the over-expression of TPI and the production of anti-TPI autoantibodies remains to 
be examined.    
 
On another note, IgM-type autoantibodies against TPI have been found in patients 
with acute hepatitis A virus infection (Ritter et al., 1994; Yang et al., 2007). These 
antibodies were believed to cause hemolytic anemia by inhibiting TPI. The 
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conversion of these antibodies to the IgG subtype was not observed, so it is unlikely 
that the IgG-type antibodies have similar pathological effects.  
 
In our study, FH was found to be associated with cirrhosis and HCC (Table 3.2). 
Contrastingly, FH was down-regulated in both moderately and poorly differentiated 
HCC (Figure 3.12). Furthermore, a paper by Liang et al. (2005) demonstrated that FH 
was down-regulated in well-differentiated HCC. Li et al. (2005) and Sun et al. (2007) 
also reported similar findings in HCC. It is thus apparent that the production of anti-
FH autoantibodies in HCC is not due to overexpression of FH.  
 
4.2.2.4.4. Proteins with Other Functions 
 
Four autoantigens – adipophilin, PCBP1, CAPZ1, and ES1 – are proteins with 
differing functions (Table 3.2; Table 3.3).  
 
Adipophilin 
In this study, autoantibodies against adipophilin were found in association with 
cirrhosis. Adipophilin has not been reported to be associated with cirrhosis or HCC. 
Instead, the protein is up-regulated in renal cell carcinoma (RCC) (Rae et al., 2000). 
Intriguingly, RCC patients expressing high levels of adipophilin purportedly had a 
better prognosis (Yao et al., 2007). Adipophilin also possessed a T-cell epitope: 
Schmidt et al. (2004), using a peptide derived from adipophilin, induced cytotoxic T-
cell responses that resulted in tumour cell lysis. However, autoantibodies against 
adipophilin have not been demonstrated in RCC or other cancers. The basis for the 
humoral response against adipophilin found in this study was unknown. Part of the 
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reason could be due to the association of adipophilin with the plasma membrane in 
HCC, as adipophilin was not found to be overexpressed in our HCC tissues.  
 
PCBP1 
Table 3.2 showed that PCBP1 was associated with cirrhosis. PCBP1 is a nucleic-acid 
binding protein with undefined functions (Dai et al., 2006; Evans et al., 2003). It has 
been found to be up-regulated in lung cancer, and is glycosylated in a HCC cell line 
with negligible metastatic potential (Cho et al., 2006; Dai et al., 2006). PCBP1 was 
not found to be glycosylated in this study (Figure 3.11), although admittedly, the 
glycoprotein detection kit utilized was not extremely sensitive. The mechanism by 
which PCBP1 induced the production of autoantibodies in HCC is thus still unknown. 
 
CAPZ1 
Autoantibodies against CAPZ1 were found in association with cirrhosis and HCC 
(Table 3.2). Such autoantibodies have also been discovered in patients with acute 
leukemia and lung cancer (Cui et al., 2005; Yang et al., 2007) as well as in patients 
with rheumatoid arthritis (Matsuo et al., 2006). Again, the basis behind the induction 
of anti-CAPZ1 autoantibodies is not known. However, CAPZ1 can bind to binding 
partners of CD2, a T-cell surface protein that is required for the interaction between 
the T-cell and an antigen-presenting cell (Hutchings et al., 2003). This association is 
thought to mediate mutual interactions between the actin cytoskeletal network and 
CD2. It could be that this association rendered CAPZ1 vulnerable to the humoral 




ES1 is a protein with unknown functions, and is not a known autoantigen. In this 
study, autoantibodies against ES1 were found to be associated with cirrhosis and 
poorly differentiated HCC (Table 3.2). These autoantibodies were also detected in 
patients with moderately differentiated HCC, albeit not in a significant number of 
patients. From Figure 3.12, ES1 was under-expressed in moderately and poorly 
differentiated HCC. The basis for the induction of anti-ES1 autoantibodies in our 
study remains to be investigated. 
 
4.2.2.5. Non-Specific Autoantigens 
 
Normal sera from many different healthy volunteers reportedly contain autoantibodies 
to self-antigens (Comtesse et al., 2000; Uemura et al., 2003; Hong et al., 2004). The 
reason behind this phenomenon is still unknown. (Comtesse et al., 2000). One 
possible explanation is that the autoantibodies were elicited under non-malignant 
conditions such as viral infections or other inflammatory processes (Sahin et al., 
1995). There is apparently no consistent trend to the autoantibodies elicited. Indeed, 
Li et al. (2006) screened 36 sera from healthy Chinese individuals and found that 
most autoantibodies, with the exception of those against α-enolase, were found at a 
low frequency.   
 
In this study, eight non-specific antigens that reacted with both normal and patient 
sera were found. These antigens are listed in Table 3.4. Notably, these antigens 
reacted with the majority of both normal and patient sera; there was not an antigen 
that reacted solely with normal sera. Another point to note is that these non-specific 
antigens tend to react strongly with patient sera and, to a lesser extent, normal sera. 
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There appeared to be no consistent characteristic amongst the non-specific antigens, 
although generally, as observed from silver-stained gels, they tended to be abundant 
proteins.  
 
Generally, none of the eight non-specific antigens in Table 3.4 was reported to elicit 
autoantibodies specifically in HCC and not in other diseases.  
 
4.2.2.6. Summary  
 
In this study, twelve cirrhosis- and HCC-associated autoantigens had been identified. 
The identity of these autoantigens were determined by tandem MS and validated 
independently by western blot using commercial antibodies. The mechanism of how 
these autoantigens triggered the production of autoantibodies is still unclear. In an 
attempt to answer the question, experiments were conducted to investigate the 
expression levels of the autoantigens in HCC tumourous tissues versus non-
tumourous tissues. Further experiments were performed to determine whether the 
autoantigens were glycosylated or phosphorylated.    
 
The autoantigens were found to be associated with different stages of HCC 
development.   In consideration of this association, six autoantigens were chosen that 
could be incorporated into a TAA panel that would enable early HCC detection and 
facilitate risk stratification. Some of the autoantigens were novel whereas some had 
been identified in other diseases. This indicated that individually, the autoantigens 
lack sensitivity and specificity. However, as a biomarker panel, it was possible for the 
autoantigens to attain improved sensitivity and specificity levels. The sensitivity and 
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specificity of the TAA panel must be determined with a new and larger set of patient 
and control sera before they can be used in the clinics. 
 
4.3. ISSUES TO CONSIDER  
 
In this study, cirrhosis- and/or HCC-associated autoantibodies that could enable early 
HCC detection were identified with a SERPA approach. Several suggestions and 
considerations are discussed below.  
 
4.3.1. Types of Sera Analyzed 
 
The antigen source was probed against sera from three groups of patients: those with 
cirrhosis, those with moderately differentiated HCC, and those with poorly 
differentiated HCC. The control sera comprised of sera from healthy individuals. 
Cirrhosis and some cases of moderately differentiated HCC could be considered early 
HCC. Nevertheless, there are disease stages preceding cirrhosis, and cirrhosis has 
varying stages of severity. In this study, the different grades of cirrhosis were not 
differentiated due to lack of clinical data.  
 
Figure 1.1 shows the progression of HBV-associated HCC. The first disease stage is 
chronic HBV infection, which is followed by fibrosis which in turn develops into 
cirrhosis. There are three grades of cirrhosis, from Child’s-Pugh A to Child’s-Pugh C, 
with Child’s-Pugh C being advanced cirrhosis (Table 1.3). Cirrhosis can lead to well 
differentiated HCC, to moderately differentiated, and finally to poorly differentiated 
HCC. In order to elucidate autoantibodies that can distinguish between the different 
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stages of HCC, the patient sera tested should include sera from patients with fibrosis; 
the three stages of cirrhosis; well differentiated HCC; moderately differentiated HCC; 
and poorly differentiated HCC. The control sera should include healthy individuals, as 
well as patients with chronic HBV infection. In this case, early detection of HCC 
would mean detecting patients with fibrosis, cirrhosis, well differentiated HCC, and 
some with moderately differentiated HCC. Risk stratification would tag patients with 
fibrosis as having low risk of developing HCC, and patients with cirrhosis as having 
high risk. This kind of early detection and risk stratification is important because 
patients at different disease stages require different treatment strategies (Figure 1.2).  
 
In this study, only sera from patients with cirrhosis and patients with moderately and 
poorly differentiated HCC were analyzed due to the shortage of sera from patients 
with fibrosis and well differentiated HCC.  
 
In terms of control sera, sera from healthy individuals are essential. However, sera 
from patients with chronic HBV infection and patients with different autoimmune 
diseases can also be tested so as to eliminate non-specific autoantibodies. Eventually, 
the TAA panel should not only allow the differentiation of normal and HCC patients, 
but also the differentiation of chronic HBV patients and HCC patients; and HCC and 
autoimmune patients. After all, patients with chronic HBV infections, rather than 
healthy individuals, are likely to be those who would be screened for the development 
of cirrhosis and HCC. Hence the TAA panel for early HCC detection must be able to 
distinguish chronic HBV patients from HCC patients. In this study, only normal sera 
was used as controls because of a lack of adequate amounts of sera from chronic HBV 
patients and patients with autoimmune diseases. In tests determining the specificity 
  107
and sensitivity of the proposed TAA panel, control sera comprising sera from patients 
with chronic HBV infection and autoimmune diseases would be essential. 
 
4.3.2. Expression Levels of Autoantigens in Cirrhotic Tissues 
 
In this study, autoantigens were examined for differential regulation of protein 
expression in moderately differentiated and poorly differentiated HCC tissues (Figure 
3.12). It would be useful to determine if these autoantigens are also differentially 
regulated in cirrhotic tissues. One difficulty, however, lies in the availability of non-
cirrhotic tissues in patients with cirrhosis. The liver of a patient with HCC usually has 
tumourous and non-tumourous regions; the liver is not usually completely tumourous. 
On the other hand, cirrhosis affects the entire liver, so it is difficult to detect non-
cirrhotic regions, especially while conducting a biopsy. In view of this, protein 
expression of the autoantigens in cirrhotic tissues could be examined relative to that in 












4.4. FUTURE PROSPECTS 
 
In this study, a proposed TAA panel consisting of six autoantigens was identified 
(Table 4.1). Future work involving the validation of the specificity and sensitivity of 
the panel is essential. Aside from this, the autoantigens identified may also be useful 
as prognostic biomarkers or targets in immunotherapy.  
 
4.4.1. Validation of Results 
 
To qualify as a biomarker candidate, the sensitivity and specificity of the proposed 
TAA panel for HCC detection must be established. The TAA panel should be tested 
against a large set of patient and control sera. Patient sera should comprise of sera 
from patients with cirrhosis, and varying stages of HCC. Control sera should comprise 
of sera from healthy individuals as well as patients with chronic HBV infection, 
autoimmune diseases or other cancers. The sample size per disease category should be 
statistically significant, with at least ten sera for each disease category. To eliminate 
potential bias, sera should be obtained from various sources. Indeed, it is 
recommended that the validation phase should involve a multi-centre study. Sera from 
different hospitals, in Singapore and in other countries, should be analyzed. In 
addition, the validation should consist of two stages. The first stage involves 
determining the sensitivity and specificity of the TAA panel in enabling early HCC 
detection using a large set of sera as described above. If the sensitivity and specificity 
are deemed satisfactory, the validation proceeds to the second stage. The second stage 
involves testing the TAA panel against a blind set of sera to verify the sensitivity and 
specificity readings in the first stage. The clinical data of this blind set of sera are 
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known, but are not disclosed to the researchers. Only if the results are satisfactory can 
the TAA panel be considered for clinical trials (Anderson and LaBaer, 2005; Azad et 
al., 2006; Caron et al., 2007; Vitzthum et al., 2005; Zolg, 2006). 
 
4.4.2. Other Applications of Autoantibodies 
 
Autoantibodies may be able to serve as prognostic biomarkers that predict cancer 
recurrence. This is because some autoantibodies have been reported to disappear upon 
cancer treatment (Anderson and LaBaer, 2005). It remains to be investigated if the 
autoantibodies elucidated in this study would disappear with the removal of the 
tumour and re-appear upon tumour emergence. 
 
The ability to detect early-stage cancer is only valuable if curative treatments are 
available. Fortunately there are various options available for HCC treatment (Section 
1.1.8.4), although these are generally only applicable to patients with early-stage HCC. 
Autoantigens could potentially aid in the development of immunotherapy (Section 
1.2.3). By itself, the humoral immune response may not be very effective against 
tumours. However, together with the cytotoxic T cell responses, the tumours may be 
eliminated. It is not known if the autoantigens identified in this study could activate 
the cellular immune system, although adipophilin is found to possess a T-cell epitope. 
Notably, autoantigens that can elicit both arms of the immune system have been found 
in association with ovarian cancer (Philip et al., 2007). None of these were identified 
in our study in association with HCC. The utility of our autoantigens in 
immunotherapy remains to be investigated. 
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4.4.3. Other Lines of Studies 
 
In this study, autoantibodies were identified based on patients with a background of 
chronic HBV infection and cirrhosis. Chronic HBV infection is prevalent in 
developing countries whereas chronic HCV infection is gaining prominence in 
developed countries. Indeed, chronic HCV infection is postulated to be responsible 
for the increasing rates of HCC incidence in the developed countries (Bruix et al., 
2004; Section 1.1.1). Like HBV-associated HCC, HCV-associated HCC tends to be 
asymptomatic. Hence, it would be advantageous to identify autoantibodies in patients 
with HCV-associated HCC. A comparison between the autoantibody profiles of 


















Biomarkers that would enable early HCC detection are urgently needed. In this regard, 
autoantibodies are excellent candidates because they may be detectable at a very early 
stage of the disease. Moreover, tests involving autoantibodies are relatively non-
invasive since autoantibodies are present in serum.  
 
In this study, twelve unique autoantigens and their corresponding autoantibodies were 
identified that were associated with various stages of HCC development. Of these, six 
were incorporated into a biomarker panel meant for early HCC detection. It is 
imperative that the clinical significance, sensitivity and specificity of this biomarker 
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